Condensed quinone oxime imidazole, condensed quinone oxime imidazolium derivatives, and their production and use

Novel fused quinone oximimidazoles and oximimidazolium derivatives address the toxicity issues of current cancer treatments by providing effective, low-toxicity anticancer drugs with high antitumor activity.

JP2024545520AActive Publication Date: 2024-12-09SHANGHAI JIAOTONG UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024536034
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-03-07
Filing Date
2022-08-17
Publication Date
2024-12-09
Estimated Expiration
2042-08-17

AI Technical Summary

Technical Problem

Current cancer treatments, particularly chemotherapy, suffer from high toxicity and the need for safer, more effective anticancer drugs with low side effects.

Method used

Development of fused quinone oximimidazoles and quinone oximimidazolium derivatives with novel structures that exhibit high antitumor activity and low toxicity, synthesized through the organic fusion of quinone compounds with carbene to form oxime derivatives.

Benefits of technology

The synthesized compounds demonstrate good antitumor activity in both in vivo and in vitro tests, showing promise as safe and reliable anticancer agents with reduced toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545520000001_ABST
    Figure 2024545520000001_ABST
Patent Text Reader

Abstract

The present invention discloses condensed quinone oxime imidazole and condensed quinone oxime imidazolium derivatives having structures represented by the following general formulas (I), (II), (III), and (IV), and their production and use. [Formula 1] TIFF2024545520000167.tif61170Their structure is novel, and the substituted quinone imidazole and substituted quinone imidazolium derivatives are condensed with aromatic carbocyclic or heterocyclic rings and characterized by oxime substitution.The in vivo and in vitro tests of the derivatives show good tumor cell growth inhibition activity, good selectivity, and good prospects for antitumor application.Their antiviral and antibacterial effects are also very good.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the field of medicine and relates to condensed quinone oxime imidazole, condensed quinone oxime imidazolium derivatives and their preparation and use, in particular to antibacterial and antiviral quinone oxime imidazolium derivatives useful for the treatment of cancer and their preparation, as well as novel synthetic intermediates and their preparation. [Background technology]

[0002] Quinone-containing compounds are widely found in nature, and many of them have good biological activity. For example, doxorubicin and mitomycin C are used as clinically applied chemotherapy drugs to treat various cancers, and alkane and its derivatives have various biological activities such as anti-inflammatory, anticancer, antiviral, antithrombotic, hypoglycemic, and hepatoprotective. Synthetic quinone-containing drugs are also widely used, for example, doxorubicin and epirubicin are both very good first-choice anticancer drugs. In recent years, research on the anticancer activity of quinone-containing active substances has been attracting attention. Nitrogen heterocyclic carbene is a metal organic catalytic ligand and small molecule catalyst with excellent activity and very wide application, and has the characteristics of high effectiveness, easy availability, easy modification, and low cost. This is highly consistent with the characteristics of drug molecules.

[0003] There are mainly two types of structural modifications of quinone-based imidazole derivatives reported in the existing literature. One is the sporadic development of accidental and unsystematic monosubstituted imidazole products (US Patent US20090163545A1 20090625, International Patent WO2009023773A2 20090219, WO2012149523A1 20121101), and the other is the introduction of a fixing group at the 2-position of naphthoquinone imidazole to modify the imidazole structure and synthesize 2-position substituted naphthoquinone imidazole non-carbene precursor derivatives (JP2014156400A 20140829, US Patent US20150086535A1 20150326, International Patent 2001060803A1 20010823, 2004092160A1 20041028, 2012161177A1 20121129, 2013148649A1 20131003, 2014142220A1 20140918). The present invention utilizes the idea of ​​academic integration to organically combine quinone compounds with carbene to form oximes, thereby designing and synthesizing a series of quinone oxime imidazolium derivatives with high anticancer activity for the first time. Summary of the Invention

[0004] At present, cancer treatment is mainly centered on chemotherapy, but the toxicity of chemotherapeutic drugs used in clinical practice cannot be ignored, so there is an urgent need to develop anti-cancer drugs that have high activity, low toxicity, and are safe and reliable. In the present invention, as a result of intensive research into quinone-based drugs, the toxicity of quinone-based compounds is mainly derived from ROS generated by the conversion of quinone to quinone oxime, and the natural quinone oxime product, alkanine, has excellent anti-cancer activity. Therefore, the object of the present invention is to provide condensed quinone oxime imidazole, condensed quinone oxime imidazolium derivatives and their preparation and use. These compounds have novel structures, are easy to prepare, show good anti-tumor activity in in vivo and in vitro tests, have low toxicity, are safe and reliable.

[0005] The object of the present invention is achieved by the following technical means.

[0006] In a first aspect, the present invention relates to fused quinone oxime imidazolium derivatives represented by the following general formulas (I) and (II):

[0007] Its structural formula is as follows: [ka] The symbols in the formula have the following meanings:

[0008] Ring A is selected from an aromatic ring having no or more than one substituent, or a heteroaromatic ring having no or more than one substituent; R 1 , R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom, a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, or a heteroaryl group having no substituents or one or more substituents, The above A ring and R 1 , R 2 , R 3 and R 4 may be selected from the groups in Group B; Group B includes a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, a heteroaryl group having no substituents or one or more substituents, -OR a , -SR a , -O-lower alkylene-OR a , -O-lower alkylene-O-lower alkylene-OR a , -O-lower alkylene-O-lower alkylene-O-lower alkylene-OR a , -O-lower alkylene-NR a R b , -O-lower alkylene-O-lower alkylene-NR a R b , -O-lower alkylene-NR c -Lower alkylene-NR a R b , -O-CO-NR a R b , -SOR a , -SO2R a , -SO2NR a R b , -NR a -SO2R b , -NR a R b , -NR c -Lower alkylene-NR a R b , -N(-lower alkylene-NR a R b )2, -NO2, -CN, -Halogen, -CO2R a , -COO - , -CONR a R b , -CONR a -OR b , -NR a -COR b , -NR a -CO-NR b Rc , -OCOR a and -COR a and R a , R b and R c are the same or different and each represents a hydrogen atom, a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, a heteroaryl group having no substituents or one or more substituents, a lower alkylene-(a 5-7 membered saturated heterocyclic group having no substituents or one or more substituents), a lower alkylene-(a cycloalkyl group having no substituents or one or more substituents), a lower alkylene-(an aryl group having no substituents or one or more substituents), or a lower alkylene-(a heteroaryl group having no substituents or one or more substituents), X - is a counter anion including halogen ions, sulfonate ions (methanesulfonate ions, trifluoromethanesulfonate ions, benzenesulfonate ions, p-toluenesulfonate ions, etc.), acetate ions, trifluoroacetate ions, carbonate ions, sulfate ions, etc., and when the anion on the substituent forms an intramolecular salt with the imidazolium cation, X - does not exist.

[0009] As one embodiment of the present invention, in the above structural formula: A ring is selected from an aromatic ring having no or at least one substituent, the substituent being NO2; R 1is selected from a hydrogen atom, a lower chain alkyl group having no or more than one substituent, a lower chain alkenyl group having no or more than one substituent, a lower alkynyl group having no or more than one substituent, an aryl group having no or more than one substituent, The substituents are -cycloalkyl groups, -aryl groups, -OR a , -O-lower chain alkyl-OR a , -O-lower chain alkyl-O-lower chain alkyl-OR a , -OR a R is selected from the group consisting of a -substituted aryl group, a -halogen substituted aryl group, a -CF3 substituted aryl group, a -NO2 substituted aryl group, and a -NH2 substituted aryl group; a is selected from a hydrogen atom, an aryl group, a lower chain alkyl group, or an aryl group-substituted lower chain alkyl group; R 2 is selected from -lower chain alkyl groups having no or one or more substituents; R 3 represents a hydrogen atom, a lower chain alkyl group having no or one or more substituents, a cycloalkyl group, an aryl group, a heterocyclic group, a lower chain alkyl-substituted aryl group, an OR a and / or a halogen-substituted aryl group, a heteroaryl group, a lower chain alkyl-substituted heteroaryl group; The substituents are -heteroaryl groups, -halogens, -lower chain alkyl substituted heteroaryl groups, and R a is a lower chain alkyl group, R 4 is selected from a hydrogen atom, a lower chain alkyl group having no or more than one substituent, a lower chain alkenyl group having no or more than one substituent, a lower alkynyl group having no or more than one substituent, a cycloalkyl group, an aryl group having no or more than one substituent, The substituents are -CN, a lower chain alkyl group, a halogen, OR a Substituted aryl group, OR a , heteroaryl groups, aryl groups, halogen-substituted aryl groups, -CORa , saturated heterocyclic group, -O-lower chain alkyl-OR a and R a is a lower chain alkyl group.

[0010] In another embodiment of the present invention, in the above structure: Ring A is selected from a benzene ring, a naphthalene ring, or an NO2-substituted benzene ring; R 1 is selected from -hydrogen atom, -lower alkyl group, -lower alkynyl group, -lower alkenyl group, -lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-O-aryl group, -lower chain alkyl-O-lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-O-lower chain alkyl-O-lower chain alkyl group-O-lower chain alkyl group, -aryl group, -5- to 7-membered saturated heterocycle, and -heteroaryl group; R 2 is selected from lower chain alkyl groups, R 3 is selected from -hydrogen atom, -lower chain alkyl group, -3 to 7 membered saturated cycloalkyl group, -heterocyclic group, -aryl group, -lower chain alkyl substituted aryl group, -halogen substituted aryl group, -heteroaryl group, -lower chain alkyl substituted heteroaryl group, -O-lower chain alkyl group, -S-lower chain alkyl group, -acyl group, -lower alkyl substituted acyl group, R 4 is a hydrogen atom, a lower chain alkyl group, a lower chain alkenyl group, a lower alkynyl group, an aryl group, -CN, a 3- to 7-membered saturated cycloalkyl group, a halogen-substituted aryl group, a lower alkyl-substituted aryl group, a heteroaryl group, or a COR a , -saturated heterocyclic group, -lower chain alkyl-OR a , -lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-S-lower chain alkyl group, -lower chain alkyl-O-lower chain alkyl-OR a Selected from R a is a lower chain alkyl group.

[0011] In another embodiment of the present invention, in the above structure: Ring A is selected from a benzene ring, a naphthalene ring, or an NO2-substituted benzene ring; R 1 is a hydrogen atom, a C1-C6 linear or branched alkyl group, a benzyl group, a C4-C6 methylcycloalkyl group, a C3-C6 alkenyl group, a -CH2(C6H 5-m -X m ) (m=1 to 5, X is a halogen atom, NO2, a hydrogen atom or -OC n H 2n+1 where n = 1 to 6), -CH2(C6H4-CH n X 3-n ) (n=1 to 3, X is a halogen atom), -(C n H 2n -O) y -C m H 2m+1 (n=1-6, m=1-6, y=1-3), -C n H 2n -OC m H 2m -Ph(n=1-6, m=1-6), -C n H 2n -NH2 (n = 1 to 6) or -CH2CH(-OCH2CH2O-), R 2 is selected from lower chain alkyl groups, R 3 is selected from a hydrogen atom, a C1-C6 linear or branched alkyl group, a C4-C6 methylcycloalkyl group, a heteroaryl group, a phenyl group or a substituted phenyl group; R 4 is selected from a -C1 to C6 straight chain alkyl group or branched chain alkyl group, a -C3 to C6 methylcycloalkyl group, a -lower alkylene-O-lower alkyl group, a -C3 to C6 alkenyl group, a -benzyl group or a substituted benzyl group, an -ester group or a substituted ester group, a -phenyl group or a substituted phenyl group, -CH2(thienyl), or -CH2CH(-OCH2CH2O-).

[0012] In another embodiment of the present invention, in the above structure: Ring A is selected from a benzene ring, a naphthalene ring, or an NO2-substituted benzene ring; R 1 is a hydrogen atom, a C1-C6 linear or branched alkyl group, a benzyl group, a C4-C6 methylcycloalkyl group, a C3-C6 alkenyl group, a -CH2(C6H 5-m -X m ) (m=1 to 5, X is a halogen atom, NO2, a hydrogen atom or -OC n H 2n+1 where n = 1 to 6), -CH2(C6H4-CH n X 3-n ) (n=1 to 3, X is a halogen atom), -(C n H 2n -O) y -C m H 2m+1 (n=1-6, m=1-6, y=1-3), -C n H 2n -OC m H 2m -Ph(n=1-6, m=1-6), -C n H 2n -NH2 (n = 1 to 6) or -CH2CH(-OCH2CH2O-), R 2 is selected from lower chain alkyl groups, R 3 is selected from a hydrogen atom, a methyl group, a phenyl group or a substituted phenyl group, R 4 is selected from -C1 to -C6 linear alkyl groups or branched alkyl groups, X is selected from Br, I, OMs, OTs.

[0013] In another embodiment of the invention, the derivative comprises:

[0014] (E)- or (Z)-4-(hydroxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-ethyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-propyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z )-1-butyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-isopropyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-isobutyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z) -1-(2-methylbutyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-tert-butyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-cyclopropyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium , (E)- or (Z)-1-(2-methoxyethyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(3-methyl-2-en-1-yl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-benzyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(2-ethoxy-2-oxyethyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-phenyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(2,4,6-trimethylphenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, 9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(thiophene-2-methyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-((1,3-dioxan-2-yl)methyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(4-fluoro benzyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(2-fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(3-fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, ( E)- or (Z)-1-(4-fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(2-fluorobenzyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(3-fluorobenzyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(4-methoxyphenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(4-methoxybenzyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(3-chloro-4-fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9 -dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-(3-bromo-4-fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium, (E)- or (Z)-1-butyl-4-(methoxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-1-butyl-4-(ethoxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium 1-Butyl-4-(benzyloxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium; (E)- or (Z)-1-butyl-4-(ethoxyimino)-3-ethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium; (E)- or (Z)-4-(benzyloxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium; (E)- or (Z)-4-(ethoxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium; (E)- or (Z)-4-(benzyloxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-3-ethyl-4-(methoxyimino)-1-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-(isopropoxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-(butoxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-(isobutoxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-(tert-butoxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-(cyclopropylmethacrylate) (E)- or (Z)-4-((allyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((4-methoxybenzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((4-benzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, 4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((4-trifluoromethylbenzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((4-fluorobenzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-(perfluorobenzyloxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro b)-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((4-nitrobenzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((2-methoxyethoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((2-(benzyloxy)ethoxy)imino))-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((2-(2-methoxyethoxy)ethoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((2-(2-(2-methoxyethoxy)ethoxy)ethoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, (E)- or (Z)-4-((benzyloxy)imino)-1-butyl-3-methyl-9-oxo-2-(3,4,5-trimethoxyphenyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, etc.

[0015] In a second aspect, the present invention further relates to a pharmaceutical composition comprising one or more of the quinone oxime imidazolium derivatives described above and a pharma- ceutically acceptable carrier.

[0016] In a third aspect, the present invention further relates to the use of said pharmaceutical composition in the manufacture of an anti-cancer, anti-bacterial or anti-viral medicament.

[0017] In a fourth aspect, the present invention further relates to a (Z) or (E) fused quinone oxime imidazole derivative represented by the following general formulas (III) and (IV) and a hydrochloride salt thereof.

[0018] Its structural formula is as follows: [ka] Ring A is selected from an aromatic ring having no or more than one substituent, or a heteroaromatic ring having no or more than one substituent; R 1 , R 3 and R 4are the same or different and each represents a hydrogen atom, a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, or a heteroaryl group having no substituents or one or more substituents, The above A ring and R 1 , R 2 , R 3 and R 4 may be selected from the groups in Group B; Group B includes a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, a heteroaryl group having no substituents or one or more substituents, -OR a , -SR a , -O-lower alkylene-OR a , -O-lower alkylene-O-lower alkylene-OR a , -O-lower alkylene-O-lower alkylene-O-lower alkylene-OR a , -O-lower alkylene-NR a R b , -O-lower alkylene-O-lower alkylene-NR a R b , -O-lower alkylene-NR c -Lower alkylene-NR a R b , -O-CO-NR a R b , -SOR a , -SO2R a , -SO2NRa R b , -NR a -SO2R b , -NR a R b , -NR c -Lower alkylene-NR a R b , -N(-lower alkylene-NR a R b )2, -NO2, -CN, -Halogen, -CO2R a , -COO - , -CONR a R b , -CONR a -OR b , -NR a -COR b , -NR a -CO-NR b R c , -OCOR a and -COR a and R a , R b and R c are the same or different and each represents a hydrogen atom, a lower chain alkyl group which is not substituted or has one or more substituents, a lower chain alkenyl group which is not substituted or has one or more substituents, a lower alkynyl group which is not substituted or has one or more substituents, a saturated heterocyclic group which is not substituted or has one or more substituents, a cycloalkyl group which is not substituted or has one or more substituents, a cycloalkenyl group which is not substituted or has one or more substituents, an aryl group which is not substituted or has one or more substituents, or a heteroaryl group which is not substituted or has one or more substituents, and the substituent refers to a lower alkyl group or a heteroalkyl group.

[0019] In one embodiment, in the above structure: A ring is selected from an aromatic ring having no or at least one substituent, the substituent being NO2; R 1is selected from the group consisting of a hydrogen atom, a lower chain alkyl group having no or more than one substituent, a lower chain alkenyl group having no or more than one substituent, and a lower alkynyl group having no or more than one substituent; The substituents are -cycloalkyl groups, -aryl groups, -OR a , -O-lower chain alkyl-OR a , -O-lower chain alkyl-O-lower chain alkyl-OR a , -OR a R is selected from the group consisting of a -substituted aryl group, a -halogen substituted aryl group, a -CF3 substituted aryl group, a -NO2 substituted aryl group, and a -NH2 substituted aryl group; a is selected from a hydrogen atom, an aryl group, a lower chain alkyl group, or an aryl group-substituted lower chain alkyl group; R 3 represents a hydrogen atom, a lower chain alkyl group having no or one or more substituents, a cycloalkyl group, an aryl group, a lower chain alkyl substituted aryl group, an OR a and / or halogen-substituted aryl group, -heteroaryl group, The substituents are -heteroaryl groups, -halogens, -lower chain alkyl substituted heteroaryl groups, and R a is a lower chain alkyl group, R 4 is selected from a hydrogen atom, a lower chain alkyl group having no or more than one substituent, a lower chain alkenyl group having no or more than one substituent, a lower alkynyl group having no or more than one substituent, a cycloalkyl group, an aryl group having no or more than one substituent, The substituents are -CN, -lower chain alkyl groups, -halogen, -OR a Substituted aryl group, -OR a , -heteroaryl group, -aryl group, -halogen-substituted aryl group, -COR a , -saturated heterocyclic group, -O-lower chain alkyl-OR a and R a is a lower chain alkyl group.

[0020] In another embodiment, in the above structure: A ring is selected from an aromatic ring having no or at least one substituent, the substituent being NO2; R 1 is selected from the group consisting of a hydrogen atom, a lower chain alkyl group having no or more than one substituent, a lower chain alkenyl group having no or more than one substituent, and a lower alkynyl group having no or more than one substituent; The substituents are -cycloalkyl groups, -aryl groups, -OR a , -O-lower chain alkyl-OR a , -O-lower chain alkyl-O-lower chain alkyl-OR a , -OR a R is selected from the group consisting of a -substituted aryl group, a -halogen substituted aryl group, a -CF3 substituted aryl group, a -NO2 substituted aryl group, and a -NH2 substituted aryl group; a is selected from a hydrogen atom, an aryl group, a lower chain alkyl group, or an aryl group-substituted lower chain alkyl group; R 3 represents a hydrogen atom, a lower chain alkyl group having no or one or more substituents, a cycloalkyl group, an aryl group, a lower chain alkyl substituted aryl group, an OR a and / or halogen-substituted aryl group, -heteroaryl group, The substituents are -heteroaryl groups, -halogens, -lower chain alkyl substituted heteroaryl groups, and R a is a lower chain alkyl group, R 4 is selected from a hydrogen atom, a lower chain alkyl group having no or more than one substituent, a lower chain alkenyl group having no or more than one substituent, a lower alkynyl group having no or more than one substituent, a cycloalkyl group, an aryl group having no or more than one substituent, The substituents are -CN, -lower chain alkyl groups, -halogen, -OR a Substituted aryl group, -OR a , -heteroaryl group, -aryl group, -halogen-substituted aryl group, -COR a, -saturated heterocyclic group, -O-lower chain alkyl-OR a and R a is a lower chain alkyl group.

[0021] In another embodiment of the present invention, in the above structure: Ring A is selected from a benzene ring, a naphthalene ring, or an NO2-substituted benzene ring; R 1 is a hydrogen atom, a C1-C6 linear or branched alkyl group, a benzyl group, a C3-C6 methylcycloalkyl group, a C3-C6 alkenyl group, or 5-m -X m ) (X is a halogen atom, NO2, a hydrogen atom or -OC n H 2n+1 where n = 1 to 6), -CH2(C6H4-CH n X 3-n ) (n=1 to 3, X is a halogen atom), -(C n H 2n -O) y -C m H 2m+1 (n=1-6, m=1-6, y=1-3), -C n H 2n -OC m H 2m -Ph(n=1 to 6, m=1 to 6) or -C n H 2n -NH2 (n = 1 to 6), R 3 is a hydrogen atom, a C1-C6 linear or branched alkyl group, a phenyl group or a substituted phenyl group, a C4-C6 methylcycloalkyl group, a heteroaryl group, n X 3-n (n=1 to 3, X is a halogen atom) or -CH2CH2(2-CH3-furyl), R 4is selected from a -C1 to C6 straight chain alkyl group or branched chain alkyl group, a -C3 to C6 methylcycloalkyl group, a -lower alkylene-O-lower alkyl group, a -C3 to C6 alkenyl group, an -alkynyl group, a -heteroaryl group, a -benzyl group or a substituted benzyl group, an -ester group or a substituted ester group, a -phenyl group or a substituted phenyl group, a -cyano group, -CH2(thienyl), -CH2CH(-OCH2CH2O-) or -CH2(pyrazinyl).

[0022] In another embodiment of the present invention, in the above structure: Ring A is selected from a benzene ring, a naphthalene ring, or an NO2-substituted benzene ring; R 1 is a hydrogen atom, a C1-C6 linear or branched alkyl group, a benzyl group, a C3-C6 methylcycloalkyl group, a C3-C6 alkenyl group, or 5-m -X m ) (X is a halogen atom, NO2, a hydrogen atom or -OC n H 2n+1 where n = 1 to 6), -CH2(C6H4-CH n X 3-n ) (n=1 to 3, X is a halogen atom), -(C n H 2n -O) y -C m H 2m+1 (n=1-6, m=1-6, y=1-3), -C n H 2n -OC m H 2m -Ph(n=1 to 6, m=1 to 6) or -C n H 2n -NH2 (n = 1 to 6), R 3 is selected from a hydrogen atom, a C1-C6 linear alkyl group, or a branched alkyl group; R 4is selected from a -C1 to C6 straight chain alkyl group or branched chain alkyl group, -lower alkylene-O-lower alkyl group, a -C3 to C6 alkenyl group, an -ester group or substituted ester group, a -phenyl group or substituted phenyl group, and a -cyano group.

[0023] In another embodiment of the invention, said derivatives include: (E)-9-(hydroxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-ethyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-propyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E )-3-isopropyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-isobutyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(2-methylbutyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(4-methoxybenzyl)-3,9-dihydro-4H-naphtho[2,3 -d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(2-methoxyethyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(3-methyl-2-en-1-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(propyl-2-yn-1-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(propyl-2-yn-1-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(thiophen-2-ylmethyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-benzyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(2-fluorobenzyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(3-fluorobenzyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(4-fluorobenzyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-2-(4-(hydroxyimino)-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazol-1-yl)acetate, (E)-3-((1,3-dioxan-2-yl)methyl)-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-11-(hydroxyimino)-3-methyl- 3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-11-(hydroxyimino)-3-ethyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-3-cyclopropyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-tert-butyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(pyra (E)-9-(hydroxyimino)-3-(2,4,6-trimethylphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(2-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(2-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9- (Hydroxyimino)-3-(3-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(4-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(4-methoxyphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(3-chloro-4-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-(3-bromo-4-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-3-methyl-8-nitro-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-(hydroxyimino)-2,3-dimethyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-methyl-3, 9-Dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-11-(hydroxyimino)-2,3-dimethyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-3-ethyl-11-(hydroxyimino)-2-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-3-isobutyl-11-(hydroxyimino)-2-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-1 1-(hydroxyimino)-2-methyl-3-(3-methyl-2-en-1-yl)-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-2-(4-(hydroxyimino)-2-methyl-11-oxo-4,11-dihydro-1H-anthracene[2,3-d]imidazol-1-yl)acetonitrile, (E)-3-benzyl-11-(hydroxyimino)-2-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-3-(4-fluorobenzyl) (E)-3-butyl-9-(hydroxyimino)-2-ethyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-propyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-2-(sec-butyl)-3-butyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-isobutyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-(pentan-3-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-tert-butyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-(2- (5-Methylfuran-2-yl)ethyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-Butyl-9-(hydroxyimino)-2-cyclobutyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-Butyl-9-(hydroxyimino)-2-phenyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-Butyl-9-(hydroxyimino)-2-(4-isopropylphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, dazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-(3,4,5-trimethoxyphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-2-(3-chloro-4-methoxyphenyl)-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-naphthyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-naphthyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxy imino)-2-(trifluoromethyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-(furan-2-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-3-butyl-9-(hydroxyimino)-2-(thiophen-2-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-2-ethyl-11-(hydroxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-2-(furan-2-yl)-11-(hydroxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E) and (Z)-9-(methoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-(ethoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-(benzyloxyimino )-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-(isopropoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-(butoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, E) and (Z)-9-(isobutoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z) -9-(tert-butoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-((cyclopropoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-((allyloxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-3-methyl-9-(((4-methoxybenzyl)oxy)imino)-3,9-dihydro b)-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-3-methyl-9-(((4-chlorobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-3-methyl-9-(((4-trifluoromethylbenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-3-methyl-9-(((4-fluorobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-3-methyl-9-(((perfluorobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-3-methyl-9-(((4-nitrobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-11-(benzyloxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E) and (Z)-11-(butoxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, 4H-anthraquinone[2,3-d]imidazol-4-one, (E) and (Z)-11-(tert-butoxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E)-9-((2-methoxyethoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-((2-(benzyloxy)ethoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol- 4-one, (E)-9-((2-(2-methoxyethoxy)ethoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-((2-(2-(2-methoxyethoxy)ethoxy)ethoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E)-9-((3-aminopropoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-3-bu (E) and (Z)-3-butyl-9-(ethoxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-9-((benzyloxy)imino)-3-butyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-11-((methoxy)imino)-3-(2-(2-methoxyethoxy)ethyl)-3,11-dihydro-4H-antho[2,3-d]imidazol-4-one Laquinone[2,3-d]imidazol-4-one, (E) and (Z)-9-((benzyloxy)imino)-2,3-dimethyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-11-((benzyloxy)imino)-2,3-dimethyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one, (E) and (Z)-9-((benzyloxy)imino)-3-butyl-2-(3,4,5-trimethoxyphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one, (E) and (Z)-2-cyclopropyl-11-(methoxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one.

[0024] The (Z) or (E) condensed quinone oxime imidazole derivatives represented by general formula (III) and (IV) and their hydrochlorides are synthetic intermediates of the above general formula (I) and (II), and have excellent antitumor activity themselves. Therefore, in a fifth aspect, the present invention further relates to a pharmaceutical composition comprising the compound or its hydrochloride and a pharma- ceutically acceptable carrier. The pharmaceutical composition has anticancer, antibacterial and antiviral effects.

[0025] In a fifth aspect, the present invention relates to the use of the above pharmaceutical composition in the manufacture of an anti-cancer, anti-bacterial or anti-viral medicament.

[0026] The compounds of general formulae (I), (II), (III) and (IV) are further described below.

[0027] The term "lower" refers to a straight or branched hydrocarbon chain of 1 to 6 carbon atoms. A "lower alkyl group" is generally an alkyl group of 1 to 4 carbon atoms, and is particularly preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, and an isobutyl group. A "lower chain alkenyl group" is generally a vinyl group, an allyl group, a 1-propenyl group, a isopropenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, and a 3-methyl-2-butenyl group. A "lower alkynyl group" is generally an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-butynyl group, a 3-butynyl group, and a 1-methyl-2-propynyl group. An "aryl group" refers to an aromatic group, and is preferably an aryl group of 6 to 14 carbon atoms, and is most preferably a phenyl group, a naphthyl group, and a fluorenyl group. The A ring refers to a ring forming the above aryl group, and is most preferably a phenyl group or a naphthyl group. The "heteroaromatic ring" refers to a 5- or 6-membered monocyclic heteroaryl group having 1 to 4 heteroatoms selected from one or more of N, S, and O, and a bicyclic heteroaryl group formed by condensing the above with a benzene ring or a 5- or 6-membered monocyclic heteroaryl group. In this case, the 5- to 6-membered monocyclic heteroaryl group is preferably a furyl group, a thienyl group, a pyrrolyl group, an imidazolyl group, a thiazolyl group, a pyrazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, an oxadiazolyl group, a thiadiazolyl group, a triazolyl group, a tetrazolyl group, a pyridyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, or a triazinyl group, and the bicyclic heteroaryl group is preferably a benzofuranyl group, a benzothienyl group, a benzothiadiazolyl group, a benzothiazolyl group, a benzoxazolyl group, a benzoxadiazolyl group, a benzimidazole group, an indolyl group, an isoindolyl group, an indazolyl group, a quinolyl group, an isoquinolyl group, a quinazolinyl group, a quinoxalinyl group, a benzodioxolyl group, an indolizine group, an imidazopyridyl group, or a cinnolinyl group. The partially saturated heteroaryl group is, for example, a 1,2,3,4-tetrahydroquinolyl group, and more preferably a furyl group or a thienyl group.

[0028] The term "lower heteroalkyl group" refers to an alkyl group of 1 to 4 carbon atoms having 1 to 4 heteroatoms selected from one or more of N, S, and O.

[0029] The term "cycloalkyl group" refers to a cycloalkyl group having 3 to 10 carbon atoms, and particularly preferred are a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group. The term "cycloalkenyl group" refers to a cycloalkenyl group having 3 to 8 carbon atoms.

[0030] The "counter anion" is not particularly limited as long as it is an anion that is pharma- ceutically acceptable as a counter anion to the imidazolium cation, and is preferably a monovalent or divalent anion such as a halogen ion, an organic sulfonate ion, an acetate ion, a trifluoroacetate ion, a carbonate ion, or a sulfate ion, and is most preferably a halogen ion.

[0031] The term "heterocyclic group" refers to a 5- to 7-membered monocyclic saturated heterocycle or a bridged ring thereof having 1 to 4 heteroatoms selected from N, S, and O. Preferred are a tetrahydropyranyl group, a tetrahydrofuranyl group, a pyrrolidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group, a quinuclidinyl group, a piperidinyl group, and a morpholinyl group.

[0032] Due to the delocalization of the cation, the compounds of the present invention have tautomers represented by the following formulas, and the present invention includes isolated tautomers or mixtures thereof. Therefore, in the present invention, the compounds represented by 1H-imidazol-3-ium derivatives include tautomers of 3H-imidazol-1-ium derivatives and mixtures of the two isomers.

[0033] [ka]

[0034] The hydrochloride salts of (III) and (IV) of the present invention are also included in the present invention.

[0035] In some cases, the compounds (I), (II), (III) and (IV) of the present invention may have geometric isomers and tautomers depending on the type of substituents. The present invention includes both isolated forms of these isomers and mixtures thereof. In some cases, the compounds of the present invention may have asymmetric carbon atoms, and therefore, isomers that provide the asymmetric carbon atom exist. The present invention includes mixed and isolated forms of these optical isomers. In some cases, the compounds of the present invention may form N-oxides depending on the type of substituents, and these substances are also included in the present invention. The present invention further includes various hydrates, solvates and crystalline polymorphs of the compounds (I), (II), (III) and (IV) of the present invention.

[0036] In a sixth aspect, the present invention further relates to a method for preparing said quinone oxime imidazolium derivatives and their synthetic intermediates, said method comprising the steps of: A protic solvent is used as a solvent to obtain a substituted quinone imidazole derivative [ka] (V) to R 1 Under the catalysis of ONH2·HCl and a weak base, or the corresponding R 1 The quinone oxime imidazole derivative is obtained by oximation reaction under the action of ONH2 and weak base hydrochloride. [ka] (III) and [ka] A step A for obtaining (IV); The quinone oxime imidazole derivative (III) or (IV) is reacted with the corresponding halide reagent R in an organic solvent. 2 and step B of reacting X with the quinone oxime imidazolium derivative (I) or (II) by N-alkylation.

[0037] Preferably, in step A, The substituted naphthoquinone imidazole, substituted oxyamine hydrochloride R 1The molar ratio of ONH2·HCl to the weak base is 1:1.2~5:0.001~0.01.

[0038] Preferably, the substituted oxyamine hydrochloride is selected from hydroxylamine hydrochloride, methoxyamine hydrochloride, phenoxyamine hydrochloride, benzyloxyamine hydrochloride.

[0039] In one embodiment, in step A, the weak base is selected from potassium carbonate, triethylamine, pyridine, and the like.

[0040] In one embodiment, in step A, the protic solvent is selected from methanol, ethanol, and isopropanol.

[0041] In one embodiment, in the step A, the reaction temperature is 90 to 125° C., and the reaction time is 12 to 48 hours.

[0042] In one embodiment, in step B, the quinone oxime imidazole derivative (III) or (IV) is reacted with a halide reagent R 2 The molar ratio to X is 1:1 to 1:100.

[0043] In one embodiment, in step B, the halogenated hydrocarbon is selected from methyl iodide, ethyl iodide, and the like.

[0044] In one embodiment, in step B, the organic solvent is selected from acetonitrile, ethyl acetate, tetrahydrofuran, and the like.

[0045] In one embodiment, in the step B, the reaction temperature is 50 to 120° C., and the reaction time is 8 to 48 hours.

[0046] Compounds (III) and (IV) of the present invention can be used as broad-spectrum anticancer, antibacterial and antiviral drugs, and have low toxicity and high safety.Therefore, the compounds of the present invention have growth inhibitory effect on all solid tumors and lymphomas, particularly breast cancer, cervical cancer, non-small cell lung cancer, rectal cancer, liver cancer, leukemia, prostate cancer, ovarian cancer, myeloma, esophageal cancer, pancreatic cancer, bladder cancer, melanoma, gastric cancer and other tumors.

[0047] The pharmaceutical composition of the present invention can be prepared by a conventional method using one or more compounds represented by general formulas (III) and (IV) and pharma- ceutical acceptable carriers (medicinal carriers, excipients, etc.) commonly used in the art. The pharmaceutical composition can be administered orally in the form of tablets, pills, capsules, granules, powders, liquids, inhalants, etc., or parenterally in the form of injections such as intravenous injections and intramuscular injections, suppositories, eye drops, eye ointments, transdermal liquids, ointments, transdermal patches, transmucosal liquids, transmucosal patches, etc.

[0048] The solid composition for oral administration of the present invention can be in the form of tablets, powders, granules, etc. In these solid compositions, one or more active substances are mixed with at least one inert excipient (e.g., lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium aluminum metasilicate, etc.). According to the usual process, the compound may contain inert additives such as lubricants (e.g., magnesium stearate), disintegrants (e.g., sodium starch glycolate), and cosolvents. If necessary, the tablet or pill can be coated with sugar coating or gastric or enteric coating agent.

[0049] Liquid compositions for oral administration include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, etc., and contain common inert solvents such as purified water or ethanol. In addition to the inert solvent, the compositions may contain auxiliary agents such as solubilizing agents, wetting agents, and suspending agents, sweeteners, flavorings, aromatics, and preservatives.

[0050] Injections for parenteral administration contain sterile aqueous or water-based solvents, suspensions and emulsions. Examples of aqueous solvents include distilled water for injection, physiological saline, etc. Examples of water-insoluble agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80, etc. These compositions may further contain isotonicity agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers and cosolvents. These compositions are sterilized, for example, by filtration through a sterilizing membrane, mixing with a bactericide, or irradiation. In addition, they can be manufactured into sterile solid compositions, and can be used by dissolving or suspending them in sterile water or a sterile injectable solvent before use. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] The following examples are useful for those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any manner. However, those skilled in the art may make some adjustments and improvements without departing from the concept of the present invention. All of these fall within the scope of protection of the present invention. The compounds of the present invention are not limited to the compounds described in the following examples. In the following examples, the experimental methods for which specific conditions are not specified are usually carried out according to general conditions or according to conditions proposed by the manufacturer. In addition, the synthesis of the raw material compounds of the compounds of the present invention is shown in the examples.

[0052] Example 1 2,3-Diamino-1,4-benzoquinone (20 g) was dissolved in 100 mL of formic acid, refluxed for 6 hours, cooled to room temperature, poured into ice water mixture, added ammonia water to adjust pH to 9-10, suction filtered, vacuum dried, and obtained 1,4-naphthoquinone imidazole (22 g) as a yellow solid. 1,4-naphthoquinone imidazole (0.3 g) and potassium hydroxide (0.15 g) were added in order to dimethyl sulfoxide solution (3 mL), the mixture was stirred at 50 ° C for 30 minutes, methyl iodide (0.2 mL) was added, reacted for 2 hours, water was added to precipitate a solid, suction filtered, washed with water, and vacuum dried to obtain 2-methyl-1,4-naphthoquinone imidazole (0.31 g) as a yellow solid. 2-Methylnaphthoquinoneimidazole (0.21 g), hydroxylamine hydrochloride (0.35 g), and pyridine (0.8 mL) were dissolved in ethanol (70 mL) and reacted at 90° C. for 48 hours. After the reaction was completed, a solid was precipitated in the solution, which was directly suction filtered and dried in vacuum to obtain a pale yellow solid (0.15 g), i.e., compound 1.

[0053] compound 1 [ka] (E)-9-(hydroxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.01(s,1H),8.26(d,J=0.8 Hz,2H),8.07(dd,J=8.0,4.0 Hz,1H),7.72-7.64(m,1H),7.61-7.52(m,1H),4.00(s,3H).

[0054] 13 C NMR (101 MHz, DMSO-d6) δ175.27,145.22,140.18,139.62,133.71,133.06,131.04,129.58,127.17,126.12,123.92,34.14.

[0055] HRMS(ESI): m / z theoretical value: C 12H9N3O2[M+H] + 228.0768, actual value: 228.0771.

[0056] 1,4-naphthoquinone imidazole can be reacted with different substituted halogenated hydrocarbons to prepare compounds 2 to 20 according to the method of Example 1, the materials and reaction conditions of other compounds are unchanged, and the raw materials are all commercially available.

[0057] compound 2 [ka] (E)-3-Ethyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.04(s,1H),8.36(s,1H),8.26(d,J=8.0 Hz,1H),8.10(d,J=8.0 Hz,1H),7.72-7.64(m,1H),7.60(t,J=7.2 Hz,1H),4.46(q,J=7.2 Hz,2H),1.39(t,J=8.0 Hz,3H).

[0058] 13 C NMR (101 MHz, DMSO-d6) δ174.94,144.31,140.21,140.08,133.66,133.06,131.10,129.59,126.48,126.22,123.91,42.17,16.64.

[0059] HRMS(ESI): m / z theoretical value: C 13 H 11 N3O2[M+H] + 242.0924, Actual value: 242.0927.

[0060] compound 3 [ka] (E)-3-Propyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one (E)-3-propyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz, DMSO-d6)δ13.05(s,1H),8.34(s,1H),8.26(d,J=8.0 Hz,1H),8.09(dd,J=8.0,1.0 Hz,1H),7.72-7.65(m,1H),7.59(td,J=8.0,1.0 Hz,1H),4.39(t,J=8.0 Hz,2H),1.85-1.72(m,2H),0.83(t,J=7.4 Hz,3H).

[0061] 13 C NMR (101 MHz, DMSO-d6) δ174.99,144.84,140.20,140.05,133.64,133.05,131.11,129.58,126.57,126.21,123.89,48.30,23.97,11.02.

[0062] HRMS(ESI):m / z theoretical value:C 14 H 13 N3O2[M+H] + 256.1081, measured value: 256.1084.

[0063] Compound 4

change

[0064] 13 13C NMR (101 MHz, DMSO-d6) δ 174.97, 144.77, 140.20, 140.03, 133.63, 133.04, 131.11, 129.57, 126.54, 126.22, 123.89, 46.55, 32.70, 19.48, 13.84.

[0065] HRMS (ESI): m / z calculated value: C 15 H 15 N3O2 [M + H] + 270.1237, found value: 270.1240.

[0066] Compound 5

Chem.

[0067] 13C NMR (101 MHz, DMSO-d6) δ174.95,141.88,140.23,140.16,133.33,133.04,131.27,129.61,126.36,126.16,123.78,49.64,23.06.

[0068] compound 6 [ka] (E)-3-isobutyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho [2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.05(s,1H),8.33(s,1H),8.27(dd,J=8.0,1.2 Hz,1H),8.10(dd,J=8.0,1.4 Hz,1H),7.68(td,J=8.0,1.4 Hz,1H),7.59(td,J=8.0,1.2 Hz,1H),4.26(d,J=8.0 Hz,2H),2.17-2.02(m,1H),0.84(d,J=4.0 Hz,6H).

[0069] 13 C NMR (101 MHz, DMSO-d6) δ175.08,145.17,140.19,140.03,133.64,133.07,131.13,129.59,126.69,126.22,123.90,53.53,29.52,19.75.

[0070] HRMS(ESI): m / z theoretical value: C 15 H 15 N3O2[M+H] + 270.1237, Actual value: 270.1237.

[0071] compound 7 [ka] (E)-9-(hydroxyimino)-3-(2-methylbutyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR (400 MHz, DMSO-d6) δ13.05(s,1H),8.33(s,1H),8.27(dd,J=8.0,1.2 Hz,1H),8.10(dd,J=8.0,1.4 Hz,1H),7.71-7.64(m,1H),7.60(td,J=8.0,1.2 Hz,1H),4.43-4.35(m,1H),4.24-4.16(m,1H),1.99-1.83(m,1H),1.37-1.20(m,1H),1.17-1.07(m,1H),0.85(t,J=8.0 Hz,3H),0.77(d,J=4.0 Hz,3H).

[0072] 13 C NMR(101 MHz, DMSO-d6)δ175.08,159.51,145.25,140.19,140.05,133.65,133.08,1 31.14,129.60,126.72,126.25,123.90,52.24,35.68,26.51,16.57,11.31.

[0073] HRMS(ESI):m / z theoretical value:C 16 H 17 N3O2[M+H] + 284.1394, measured value: 284.1390.

[0074] Compound 8

change

[0075] 13 C NMR (101 MHz, DMSO-d6) δ 175.10, 159.52, 159.38, 144.87, 140.11, 133.77, 133.14, 131.03, 129.59, 129.50, 129.35, 126.36, 126.22, 123.96, 114.49, 55.52, 49.10。

[0076] HRMS (ESI): m / z theoretical value: C 19 H 15 FN3O3 [M + H] + 334.1186, measured value: 334.1182。

[0077] Compound 9

Chem.

[0078] 13 C NMR (101 MHz, DMSO-d6) δ 175.16, 145.37, 140.16, 139.96, 133.69, 133.09, 131.05, 129.57, 126.48, 126.20, 123.93, 70.72, 58.48, 46.46。

[0079] HRMS (ESI): m / z theoretical value: C 14 H 13 N3O3 [M + H] + 272.1030, measured value: 272.1032。

[0080] compound 10 [ka] (E)-9-(hydroxyimino)-3-(3-methyl-2-en-1-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.03(s,1H),8.32(s,1H),8.26(dd,J=8.0,1.2 Hz,1H),8.10(dd,J=8.0,1.4 Hz,1H),7.68(td,J=8.0,1.4 Hz,1H),7.59(td,J=8.0,1.2 Hz,1H),5.44-5.35(m,1H),5.06(d,J=8.0 Hz,2H),1.77(s,3H),1.67(s,3H).

[0081] 13 C NMR(101 MHz,DMSO-d6)δ175.05,144.24,140.17,139.91,137.77,133.66,133.07 ,131.08,129.58,126.45,126.23,123.92,119.76,44.64,25.77,18.42.

[0082] HRMS(ESI): m / z theoretical value: C 16 H 15 N3O2[M+H] + 282.1237, Actual value: 282.1239.

[0083] compound 11 [ka] (E)-9-(hydroxyimino)-3-(propyl-2-alkynyl-1-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR(400 MHz,DMSO-d6)δ13.02(s,1H),8.41(s,1H),8.28(d,J=8.0 Hz,1H),8.11(d,J=8.0 Hz, 1H), 7.73-7.64 (m, 1H), 7.64-7.54 (m, 1H), 5.35 (s, 2H), 3.53 (s, 1H).

[0084] 13 C NMR (101 MHz, DMSO-d6) δ175.02,144.29,139.99,133.91,133.22,130.86,129.61,129.58,126.61,126.12,124.05,78.38,77.22,36.50.

[0085] HRMS(ESI): m / z theoretical value: C 14 H9N3O2[M+H] + 252.0768, Actual value: 252.0769.

[0086] compound 12 [ka] (E)-9-(hydroxyimino)-3-(thiophen-2-ylmethyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.01(s,1H),8.49(s,1H),8.27(d,J=8.0,1H),8.12(dd,J=7.9,1.5 Hz,1H),7.69(t,J=8.0,1H),7.60(t,J=8.0 Hz,1H),7.43(d,J=8.0 Hz,1H),7.19(d,J=4.0 Hz,1H),6.95(dd,J=8.0,4.0 Hz,1H),5.88(s,2H).

[0087] 1313C NMR (101 MHz, DMSO-d6) δ 175.20, 144.72, 140.04, 139.91, 139.42, 133.87, 133.20, 130.93, 129.60, 127.89, 127.49, 127.25, 126.19, 126.18, 124.02, 44.36.

[0088] HRMS (ESI): calculated m / z for C 16 H 11 N3O2S [M+H] + 310.0645, found 310.0642.

[0089] Compound 13

Chemical Structure

[0090] 13 13C NMR (101 MHz, DMSO-d6) δ 175.08, 145.10, 140.10, 140.06, 137.44, 133.81, 133.14, 130.98, 129.56, 129.12, 128.25, 127.72, 126.48, 126.18, 123.97, 49.58.

[0091] HRMS (ESI): calculated m / z for C 18 H 13 N3O2 [M+H] + 304.1081, found 304.1082.

[0092] Compound 14 [ka] (E)-9-(hydroxyimino)-3-(2-fluorobenzyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.04(s,1H),8.41(s,1H),8.31-8.22(m,1H),8.04(dd,J=8.0,1.4 Hz,1H),7.70-7.64(m,1H),7.62-7.54(m,1H),7.35-7.27(m,1H),7.25-7.18(m,1H),7.10(td,J=7.5,1.2 Hz,1H),7.04(td,J=8.0,1.8 Hz, 1H), 5.77(s, 2H).

[0093] 13 C NMR(101 MHz,DMSO-d6)δ175.00,163.05(160.71,J=234.0 Hz),145.45,140.08,139.99,133.88,133.16,130.90,130.45(130.37,J=8.0 Hz),129.56,129.35(129.31,J=4.0 Hz),126.66,126.15,125.19(125.15,J=4.0 Hz),124.45(124.31,J=14.0 Hz),123.99,115.92(115.71,J=21.0 Hz), 44.17 (44.12, J = 5.0 Hz).

[0094] HRMS(ESI): m / z theoretical value: C 18 H 12 FN3O2[M+H] + 322.0986, Actual value: 322.0984.

[0095] compound 15 [ka] (E)-9-(hydroxyimino)-3-(3-fluorobenzyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR (400 MHz, DMSO-d6) δ8.51(s,1H),8.27(d,J=8.0 Hz,1H),8.07(d,J=8.0 Hz,1H),7.68(t,J=8.0 Hz,1H),7.58(t,J=8.0 Hz,1H),7.40-7.30(m,1H),7.17-7.06(m,3H),5.71(s,2H).

[0096] 13 C NMR(101 MHz, DMSO-d6)δ175.12,163.82(161.39,J=243.0 Hz),145.17,140.22(140.15,J=7.0 Hz),140.10,133.87,133.17,131.22(131.14,J=8.0 Hz),130.95,129.56,126.63,126.47,126.18,123.99,123.75(123.72,J=3.0 Hz),115.21(115.00,J=21.0 Hz),114.78(114.56,J=22.0 Hz),49.06(49.05,J=1.0 Hz).

[0097] Compound 16

change

[0098] 1313C NMR (101 MHz, DMSO-d6) δ 175.11, 163.34 (160.91, J = 243.0 Hz), 145.01, 140.13, 140.09, 133.83, 133.65 (133.62, J = 3.0 Hz), 133.15, 130.96, 130.15 (130.07, J = 8.0 Hz), 129.56, 126.40, 126.19, 123.97, 116.03 (115.81, J = 22.0 Hz), 48.87.

[0099] HRMS (ESI): calculated m / z for C 18 H 12 FN3O2 [M + H] + 322.0986, found 322.0986.

[0100] Compound 17

Chemical Structure

[0101] 13 13C NMR (101 MHz, DMSO-d6) δ 175.27, 168.10, 145.42, 134.05, 133.27, 130.71, 129.61, 127.16, 126.61, 126.05, 124.13, 61.78, 48.16, 14.47.

[0102] HRMS (ESI): calculated m / z for C 15 H 13 N3O4 [M + H] +300.0979, Actual value: 300.0981.

[0103] compound 18 [ka] (E)-3-((1,3-dioxan-2-yl)methyl)-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.03(s,1H),8.30-8.20(m,2H),8.09(dd,J=8.0,1.4 Hz,1H),7.68(td,J=8.0,1.4 Hz,1H),7.59(td,J=8.0,1.2 Hz,1H),5.20(t,J=4.0Hz,1H),4.67(d,J=4.0Hz,2H),3.82-3.73(m,4H).

[0104] 13 C NMR (101 MHz, DMSO-d6) δ175.26,145.49,140.06,139.55,133.72,133.12,131.03,129.58,126.88,126.19,123.95,101.10,65.05,48.12.

[0105] HRMS(ESI): m / z theoretical value: C 15 H 13 N3O4[M+H] + 300.0979, Actual value: 300.0978.

[0106] compound 19 [ka] (E)-11-(hydroxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 11H NMR (400 MHz, DMSO-d6) δ 13.09 (s, 1H), 9.04 (s, 1H), 8.77 (d, J = 12.4 Hz, 2H), 8.15 (dd, J = 26.4, 7.7 Hz, 2H), 7.64 (d, J = 20.0 Hz, 2H), 4.03 (s, 3H).

[0107] HRMS (ESI): m / z calculated value: C 15 H 13 N3O4 [M+H] + 278.0924, found value: 278.0922.

[0108] Compound 20

Chemical Structure

[0109] HRMS (ESI): m / z calculated value: C 15 H 13 N3O4 [M+H] + 292.1081, found value: 292.1078.

[0110] (Example 2) 2,2'-(1,4-dioxy-1,4,6,7-tetralin-2,3-diyl)bis(isoindoline-1,3-dione) (13.3g) was dissolved in 200mL of dichloromethane and 20mL of methanol, cyclopropylamine was added, and the mixture was reacted for 2 hours. The solvent was removed, 100mL of water was added, and the mixture was slurried for 10 minutes. The mixture was then suction filtered to obtain a red solid (10g). 10g of the solid was directly added to 150mL of ethanol, 8mL of hydrazine hydrate (80%) was added dropwise, and the mixture was stirred at room temperature for half an hour to remove the organic phase. 200mL of water was added, and the mixture was slurried for 10 minutes. The mixture was filtered and washed with water until it became colorless, and then vacuum dried to obtain a blue solid 2-amino-3-cyclopropyl-6,7-dihydronaphthalene-1,4-dione (6.2g). 2-Amino-3-cyclopropyl-6,7-dihydronaphthalene-1,4-dione (1g) was refluxed with methyl orthoformate (25mL) for 2.5 hours, the solvent was removed, and the mixture was separated by a silica gel chromatography column to obtain a white solid 1-cyclopropyl-6,7-dihydromethane-1H-naphtho[2,3-d]imidazole-4,9-dione (0.46g). 3-Cyclopropylnaphthoquinoneimidazole (0.21g), hydroxylamine hydrochloride (0.35g), and pyridine (0.8mL) were dissolved in ethanol (70mL) and reacted at 100°C for 36 hours. After the reaction was completed, the solid was precipitated in the solution, directly suction filtered, and vacuum dried to obtain a pale yellow solid (0.15g).

[0111] Compound 21 was obtained by the method of Example 2.

[0112] compound 21 [ka] (E)-3-Cyclopropyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 11H NMR (400 MHz, DMSO-d6) δ 13.00 (s, 1H), 8.31 (s, 1H), 8.25 (dd, J = 8.0, 1.2 Hz, 1H), 8.11 (dd, J = 8.0, 1.4 Hz, 1H), 7.67 (td, J = 8.0, 1.4 Hz, 1H), 7.59 (td, J = 8.0, 1.2 Hz, 1H), 3.93 - 3.86 (m, 1H), 1.13 - 1.03 (m, 4H).

[0113] 13 13C NMR (101 MHz, DMSO-d6) δ 174.50, 143.32, 140.18, 139.97, 133.46, 132.97, 131.25, 129.58, 128.36, 126.23, 123.86, 29.61, 7.44.

[0114] HRMS (ESI): m / z theoretical value: C 14 H 11 N3O2 [M + H] + 254.0924, found: 254.0927.

[0115] (Example 3) Nitrogen-(3-chloro-1,4-dioxo-1,4,6,7-tetralin-2-yl)acetamide (0.25 g) was dissolved in 20 mL of tetrahydrofuran, triethylamine and tert-butylamine were added to the reaction solution in order, and the mixture was refluxed under a nitrogen gas atmosphere for 26 hours. After cooling to room temperature, the solvent was removed and 10 mL of ultrapure water was added and slurried for half an hour to obtain nitrogen-(3-(tert-butylamino)-1,4-dioxy-1,4,6,7-tetralin-2-yl)acetamide. It was dispersed in 85 mL of hydrazine hydrate (50%) and reacted at 80 ° C for 2 hours, extracted with dichloromethane, and the organic phase was collected and washed with saturated saline, then dried over anhydrous sodium sulfate, filtered, concentrated, and separated by a silica gel chromatography column to obtain the product 2-amino-3-(tert-butylamino)-6,7-dihydronaphthalene-1,4-dione. 50mL of triethyl orthoformate was added to 2-amino-3-(tert-butylamino)-6,7-dihydronaphthalene-1,4-dione (1.63g), and the mixture was refluxed for 3 hours, then cooled to room temperature, the solvent was removed, and the mixture was separated and purified by silica gel column chromatography to obtain the product 3-tert-butylnaphthoquinone imidazole. 3-tert-Butylnaphthoquinone imidazole (0.21g), hydroxylamine hydrochloride (0.17g), and pyridine (0.4mL) were dissolved in ethanol (50mL) and reacted at 110°C for 24 hours. After the reaction was completed, a solid was precipitated in the solution, which was directly suction filtered and vacuum dried to obtain a pale yellow solid (0.16g).

[0116] By adding different substituted amines, compounds 22-32 can be prepared by the method of Example 3, the materials and reaction conditions of other compounds are unchanged, and the raw materials are all commercially available.

[0117] compound 22 [ka] (E)-3-tert-Butyl-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 11H NMR (400 MHz, DMSO-d6) δ 13.55 (s, 1H), 8.49 (s, 1H), 8.23 (d, J = 8.0 Hz, 1H), 8.17 (d, J = 7.4 Hz, 1H), 7.68 (t, J = 8.0 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 1.72 (s, 9H).

[0118] 13 13C NMR (101 MHz, DMSO-d6) δ 173.70, 142.87, 142.71, 140.17, 132.99, 132.43, 131.66, 129.80, 127.11, 127.08, 123.26, 59.59, 29.32.

[0119] HRMS (ESI): m / z calculated value: C 15 H 15 N3O2 [M + H] + 270.1237, found value: 270.1241.

[0120] Compound 23

Chemical Structure

[0121] 13 13C NMR (101 MHz, DMSO-d6) δ 174.99, 151.72, 145.78, 144.60, 144.34, 143.98, 140.12, 139.84, 133.89, 133.16, 130.80, 129.55, 126.79, 126.08, 124.01, 49.11.

[0122] HRMS(ESI): m / z theoretical value: C 16 H 11 N5O2[M+H] + 306.0986, Actual value: 306.0985.

[0123] compound 24 [ka] (E)-9-(hydroxyimino)-3-benzyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.10(s,1H),8.47(s,1H),8.30(dd,J=8.0,1.2 Hz,1H),8.02(dd,J=8.0,1.4 Hz,1H),7.69(td,J=8.0,1.4 Hz, 1H), 7.63-7.48(m, 6H).

[0124] 13 C NMR(101 MHz,DMSO-d6)δ174.10,145.03,140.19,140.10,135.90,133.66,133.07,131.24,129.59,129.36,129.31,127.14,126.57,126.27,123.91.

[0125] HRMS(ESI): m / z theoretical value: C 17 H 11 N3O2[M+H] + 290.0924, Actual value: 290.0922.

[0126] compound 25 [ka] (E)-9-(hydroxyimino)-3-(2,4,6-trimethylphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR (400 MHz, DMSO-d6) δ13.09(s,1H),8.35-8.26(m,2H),8.00-7.95(m,1H),7.73-7.65(m,1H),7.62-7.54(m,1H),7.03(s,2H),3.34(s,9H).

[0127] 13 C NMR(101 MHz,DMSO-d6)δ174.25,144.93,140.19,139.83,138.97,135.02,133.96,133 .14,132.50,130.95,129.58,129.12,127.34,126.10,124.05,21.06,17.48.

[0128] HRMS(ESI): m / z theoretical value: C 20 H 17 N3O2[M+H] + 322.1394, Actual value: 322.1392.

[0129] compound 26 [ka] (E)-9-(hydroxyimino)-3-(2-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.09(s,1H),8.50(s,1H),8.32(dd,J=8.0,1.2 Hz,1H),8.01(dd,J=8.0,1.4 Hz,1H),7.75-7.65(m,2H),7.64-7.56(m,2H),7.51-7.44(m,1H),7.38(td,J=8.0,1.2 Hz,1H).

[0130] 13C NMR(101 MHz,DMSO-d6)δ174.23,158.18(155.70,J=248.0 Hz),145.23,139.94(139.68,J=26.0 Hz),133.93,133.26,131.86(131.78,J=8.0 Hz),130.84,129.64,129.18,127.94,127.80,126.10,125.33(125.29,J=4.0 Hz),124.21,124.10,116.75(116.55,J=20.0 Hz).

[0131] HRMS(ESI): m / z theoretical value: C 17 H 10 FN3O2[M+H] + 308.0830, Actual value: 308.0831.

[0132] compound 27 [ka] (E)-9-(hydroxyimino)-3-(3-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.08(s,1H),8.49(s,1H),8.30(dd,J=8.0,1.2 Hz,1H),8.03(dd,J=8.0,1.4 Hz,1H),7.70(td,J=8.0,1.4 Hz, 1H), 7.62-7.54 (m, 3H), 7.48-7.43 (m, 1H), 7.42-7.35 (m, 1H).

[0133] 1313C NMR (101 MHz, DMSO-d6) δ 174.15, 163.26 (160.83, J = 243.0 Hz), 145.03, 140.17 (140.02, J = 15.0 Hz), 137.30, 137.19, 133.70, 133.11, 131.17, 130.96 (130.87, J = 9.0 Hz), 129.58, 127.19, 126.28, 123.92, 122.87 (122.84, J = 3.0 Hz), 116.42 (116.21, J = 21.0 Hz), 114.56 (114.31, J = 25.0 Hz).

[0134] HRMS (ESI): m / z calculated value: C 17 H 10 FN3O2 [M + H] + 308.0830, found value: 308.0832.

[0135] Compound 28

Chem.

[0136] 13 13C NMR (101 MHz, DMSO-d6) δ 174.18, 163.67 (161.22, J = 245.0 Hz), 145.09, 140.08, 133.72, 133.10, 132.30 (132.27, J = 3.0 Hz), 131.19, 129.59, 128.95 (128.86, J = 9.0 Hz), 127.28, 126.60, 126.24, 123.93, 116.22 (115.99, J = 23.0 Hz).

[0137] HRMS(ESI): m / z theoretical value: C 17 H 10 FN3O2[M+H] + 308.0830, Actual value: 308.0829.

[0138] compound 29 [ka] (E)-9-(hydroxyimino)-3-(4-methoxyphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.07(s,1H),8.40(s,1H),8.32-8.28(m,1H),8.02(dd,J=8.0,1.4 Hz,1H),7.70(td,J=8.0,1.4 Hz, 1H), 7.59 (td, J=8.0, 1.2 Hz, 1H), 7.51-7.47 (m, 2H), 7.08-7.04 (m, 2H), 3.82 (s, 3H).

[0139] 13 C NMR(101 MHz,DMSO-d6)δ174.10,159.95,159.53,145.06,140.16,133.63,133.05, 131.28,129.59,128.73,127.82,127.23,126.25,123.90,114.40,56.00.

[0140] HRMS(ESI): m / z theoretical value: C 18 H 13 FN3O3[M+H] + 320.1030, Actual value: 320.1026.

[0141] compound 30 [ka] (E)-9-(hydroxyimino)-3-(3-chloro-4-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR (400 MHz, DMSO-d6) δ13.13(s,1H),8.52(s,1H),8.30(dd,J=8.0,1.2 Hz,1H),8.05-7.97(m,2H),7.72-7.64(m,2H),7.62-7.55(m,2H).

[0142] 13 C NMR(101 MHz,DMSO-d6)δ174.25,158.99(156.52,J=247.0 Hz),145.02,139.91,133.71,133.19,132.90(132.87,J=3.0 Hz),131.06,129.61,129.20,127.83,127.75,127.28,126.26,123.95,120.02(119.83,J=19.0 Hz),117.46(117.24 J=22.0 Hz).

[0143] HRMS(ESI): m / z theoretical value: C 17 H9ClFN3O2[M+H] + 342.0440, Actual value: 342.0438.

[0144] compound 31 [ka] (E)-9-(hydroxyimino)-3-(3-bromo-4-fluorophenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR (400 MHz, DMSO-d6) δ13.06(s,1H),8.47(s,1H),8.30(dd,J=8.0,1.2 Hz,1H),8.10-8.00(m,2H),7.72-7.66(m,2H),7.61-7.53(m,2H).

[0145] 13C NMR(101 MHz,DMSO-d6)δ174.27,159.55,145.12,140.03(139.98,J=5.0 Hz),133.77,133.16,133.15,131.83,131.11,129.59,128.45,128.37,127.34,126.25,123.96,117.20(116.96,J=24.0 Hz),108.33(108.11,J=22.0 Hz).

[0146] HRMS(ESI): m / z theoretical value: C 17 H9BrFN3O2[M+H] + 385.9935, Actual value: 385.9930.

[0147] compound 32 [ka] (E)-9-(hydroxyimino)-3-methyl-8-nitro-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR (400 MHz, DMSO-d6) δ14.67(s,1H),9.66(s,1H),8.37(d,J=7.8 Hz,1H),8.25(d,J=7.9 Hz,1H),8.09(t,J=7.8 Hz,1H),4.14(s,3H).

[0148] HRMS(ESI): m / z theoretical value: C 17 H9BrFN3O2[M+H] + 273.0619, actual value: 273.0620.

[0149] Example 4 2,3-Diamino-1,4-benzoquinone (20 g) was dissolved in 100 mL of acetic acid, refluxed for 6 hours, cooled to room temperature, poured into ice water mixture, ammonia water was added to adjust the pH to 9-10, suction filtered, and vacuum dried to obtain yellow solid 1,4-naphthoquinone imidazole (22 g). 1,4-naphthoquinone imidazole (0.3 g) and potassium hydroxide (0.15 g) were added in sequence to dimethyl sulfoxide solution (3 mL), the mixture was stirred at 50 ° C for 30 minutes, methyl iodide (0.2 mL) was added, reacted for 2 hours, water was added to precipitate a solid, suction filtered, washed with water, and vacuum dried to obtain yellow solid 2-methyl-1,4-naphthoquinone imidazole (0.31 g). 2-Methylnaphthoquinoneimidazole (0.2 g), hydroxylamine hydrochloride (0.28 g), and pyridine (0.7 mL) were dissolved in ethanol (70 mL) and reacted at 105° C. for 36 hours. After the reaction was completed, a solid was precipitated in the solution, which was directly suction filtered and dried in vacuum to obtain a pale yellow solid (0.16 g).

[0150] 2,3-Diamino-1,4-naphthoquinone (20g) is dissolved in 100mL of acetic acid and refluxed for 6 hours to obtain anthraquinone imidazole, or different substituted halogenated hydrocarbons are added and reacted to prepare compounds 33-41 according to the method of Example 4. The materials and reaction conditions of other compounds are unchanged, and the raw materials are all commercially available.

[0151] compound 33 [ka] (E)-9-(hydroxyimino)-2,3-dimethyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.01(s,1H),8.26(d,J=0.8 Hz,2H),8.07(dd,J=8.0,4.0 Hz,1H),7.72-7.64(m,1H),7.61-7.52(m,1H),4.00(s,3H),2.81(s,3H).

[0152] 13 C NMR (101 MHz, DMSO-d6) δ175.27,145.22,140.18,139.62,133.71,133.06,131.04,129.58,127.17,126.12,123.92,34.14,20.1.

[0153] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 241.0851, Actual value: 241.0854.

[0154] compound 34 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.14(s,1H),8.27(d,J=7.9 Hz,1H),8.12(dd,J=7.8,1.5 Hz,1H),7.73-7.65(m,1H),7.65-7.57(m,1H),4.41(d,J=15.1 Hz,2H),1.73-1.65(m,2H),1.32(q,J=7.4 Hz,2H),0.90(t,J=7.3 Hz,3H).

[0155] compound 35 [ka] (E)-11-(hydroxyimino)-2,3-dimethyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.09(s,1H),8.77(d,J=12.4 Hz,2H),8.15(dd,J=26.4,7.8 Hz,2H),7.64(d,J=20.0 Hz,2H),4.03(s,3H),2.54(s,3H).

[0156] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 292.1081, Actual value: 292.1082.

[0157] compound 36 [ka] (E)-3-Ethyl-11-(hydroxyimino)-2-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.87(s,1H),8.84(s,2H),8.21(dd,J=22.4,8.2 Hz,2H),7.82-7.64(m,2H),4.60(d,J=7.8 Hz,2H),2.79(s,3H),1.40(d,J=8.0 Hz,3H).

[0158] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 306.1237, Actual value: 306.1240.

[0159] compound 37 [ka] (E)-3-isobutyl-11-(hydroxyimino)-2-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.90(s,1H),8.84(s,2H),8.20(dd,J=15.0,8.4 Hz,2H),7.81-7.58(m,2H),4.41(d,J=7.0 Hz, 2H), 2.78 (s, 3H), 2.22-2.14 (m, 1H), 0.95 (d, J=6.8 Hz, 6H).

[0160] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H]+ 344.1550, Actual value: 344.1554.

[0161] compound 38 [ka] (E)-11-(hydroxyimino)-2-methyl-3-(3-methyl-2-en-1-yl)-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.44(s,1H),8.81(s,2H),8.24-8.13(m,2H),7.74-7.66(m,2H ),5.30-5.22(m,2H),5.14-5.10(m,1H),2.65(s,3H),1.84(s,3H),1.70(s,3H).

[0162] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 346.1550, Actual value: 346.1555.

[0163] compound 39 [ka] (E)-2-(4-(hydroxyimino)-2-methyl-11-oxo-4,11-dihydro-1H-anthracene[2,3-d]imidazol-1-yl)acetonitrile 1 H NMR (400 MHz, DMSO-d6) δ13.46(s,1H),8.69(s,2H),8.26(s,2H),7.76(d,J=6.4 Hz,2H),5.70(s,2H),2.59(s,3H).

[0164] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 317.1033, Actual value: 317.1035.

[0165] compound 40 [ka] (E)-3-Benzyl-11-(hydroxyimino)-2-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.01(s,1H),8.78(d,J=33.2 Hz,2H),8.15(dd,J=16.8,7.8 Hz,2H),7.65(d,J=19.9 Hz, 2H), 7.43-7.12 (m, 5H), 5.83 (s, 2H), 2.65 (s, 3H).

[0166] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 368.1394, Actual value: 368.1395.

[0167] compound 41 [ka] (E)-3-(4-fluorobenzyl)-11-(hydroxyimino)-2-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.50(s,1H),8.81(d,J=16.8 Hz,2H),8.24-8.13(m,2H),7.75-7.60(m,2H),7.16(d,J=8.8 Hz, 4H), 5.86 (s, 2H), 2.62 (s, 3H).

[0168] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 386.1300, Actual value: 386.1327.

[0169] Example 5 2,3-Diamino-1,4-benzoquinone (4g) was dissolved in 13mL of dimethylsulfoxide, butyraldehyde (2.12mL) was added, and the mixture was reacted at 80℃ for 13 hours with the lid open. After cooling to room temperature, water was slowly added to precipitate the solid, which was then suction filtered and dried in vacuum to obtain 1,4-naphthoquinone imidazole (0.15g) as a yellow solid. 1,4-naphthoquinone imidazole (0.3g) and potassium hydroxide (0.15g) were added in sequence to the dimethylsulfoxide solution (3mL), the mixture was stirred at 50℃ for 30 minutes, butyl iodide (0.2mL) was added, the mixture was reacted for 2 hours, water was added to precipitate the solid, which was then suction filtered, washed with water, and dried in vacuum to obtain 2-methyl-1,4-naphthoquinone imidazole (0.31g) as a yellow solid. 2-Methylnaphthoquinoneimidazole (0.2 g), hydroxylamine hydrochloride (0.11 g), and pyridine (0.35 mL) were dissolved in ethanol (35 mL) and reacted at 105° C. for 36 hours. After the reaction was completed, a solid was precipitated in the solution, which was directly suction filtered and vacuum dried to obtain a pale yellow solid (0.15 g).

[0170] Compounds 42 to 59 can be prepared by the method of Example 5 by dissolving 2,3-diamino-1,4-benzoquinone (4 g) in 13 mL of dimethyl sulfoxide and reacting with different aldehydes, or dissolving 2,3-diamino-1,4-naphthoquinone (20 g) in dimethyl sulfoxide and reacting with different aldehydes, or adding different substituted halogenated hydrocarbons. The materials and reaction conditions for other compounds are the same, and the raw materials are all commercially available.

[0171] compound 42 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-ethyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 11H NMR (400 MHz, DMSO-d6) δ 13.26 (s, 1H), 8.25 (d, J = 7.9 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.75 - 7.65 (m, 1H), 7.60 (t, J = 7.5 Hz, 1H), 4.38 (t, J = 7.5 Hz, 2H), 2.86 (q, J = 7.5 Hz, 2H), 1.67 (ddd, J = 12.6, 10.2, 6.5 Hz, 2H), 1.31 (td, J = 7.5, 3.7 Hz, 5H), 0.89 (t, J = 7.4 Hz, 3H).

[0172] HRMS (ESI): m / z calculated value: C 12 H9N3O2 [M + H] + 298.1550, measured value: 298.1557.

[0173] Compound 43

Chem.

[0174] HRMS (ESI): m / z calculated value: C 12 H9N3O2 [M + H] + 312.1707, measured value: 312.1709.

[0175] Compound 44

Chem.

[0176] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 326.1863, Actual value: 326.1865.

[0177] compound 45 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-isobutyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,Chloroform-d)δ13.91(s,1H),8.38(d,J=7.8 Hz,1H),8.21(d,J=7.8 Hz,1H),7.62(t,J=7.6 Hz,1H),7.54(t,J=7.6 Hz,1H),4.44(t,J=7.8 Hz,2H),2.68(d,J=7.0 Hz,2H),2.32(dp,J=13.8,6.8 Hz,1H),1.78(p,J=7.6 Hz,2H),1.44(p,J=7.4 Hz,2H),1.11-0.91(m,9H).

[0178] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 326.1863, Actual value: 326.1862.

[0179] compound 46 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-(pentan-3-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,Chloroform-d)δ14.05(s,1H),8.44(dd,J=8.0,1.2 Hz,1H),8.29-8.20(m,1H),7.67(td,J=7.6,1.6 Hz,1H),7.59(td,J=7.6,1.4 Hz,1H),4.57-4.46(m,2H),2.79(tt,J=8.4,5.6 Hz,1H),1.92-1.80(m,6H),1.49(h,J=7.4 Hz,2H),1.02(t,J=7.4 Hz,3H),0.90(t,J=7.4 Hz,6H).

[0180] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 340.2020, actual value: 340.2025.

[0181] compound 47 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-tert-butyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 11H NMR (400 MHz, Chloroform-d) δ 14.09 (s, 1H), 8.40 (d, J = 7.8 Hz, 1H), 8.25 (d, J = 7.8 Hz, 1H), 7.64 (t, J = 7.2 Hz, 1H), 7.56 (t, J = 7.8 Hz, 1H), 4.62 - 4.49 (m, 2H), 1.95 - 1.85 (m, 2H), 1.60 - 1.53 (m, 11H), 1.03 (t, J = 7.2 Hz, 3H).

[0182] HRMS (ESI): m / z calculated value: C 12 H9N3O2 [M + H] + 326.1863, found: 326.1864.

[0183] Compound 48

Chem.

[0184] HRMS (ESI): m / z calculated value: C 12 H9N3O2 [M + H] + 378.1812, found: 378.1813.

[0185] Compound 49

Chem.

[0186] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 324.1707, Actual value: 324.1709.

[0187] compound 50 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-phenyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,Chloroform-d)δ13.92(s,1H),8.46(d,J=7.8 Hz,1H),8.29(d,J=7.8 Hz,1H),7.69(d,J=7.4 Hz,2H),7.63-7.58(m,5H),4.58(t,J=7.8 Hz,2H),1.86(q,J=7.6 Hz,2H),1.37-1.31(m,2H),0.89(t,J=7.2 Hz,3H).

[0188] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] +346.1550, Actual value: 346.1554.

[0189] compound 51 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-(4-isopropylphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,Chloroform-d)δ13.96(s,1H),8.44(d,J=7.8 Hz,1H),8.28(dd,J=78,1.6 Hz,1H),7.93-7.54(m,4H),7.52-7.31(m,2H),4.57(t,J=7.8 Hz,2H),1.92-1.83(m,2H),1.42-1.25(m,8H),0.90(t,J=7.4 Hz,3H).

[0190] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 388.2020, actual value: 388.2024.

[0191] compound 52 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-(3,4,5-trimethoxyphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,Chloroform-d)δ13.85(s,1H),8.45(d,J=7.8 Hz,1H),8.29(d,J=7.8 Hz,1H),7.68(t,J=8.0 Hz,1H),7.60(t,J=7.4 Hz,1H),6.88(s,2H),4.63-4.52(m,2H),3.94(s,9H),1.92-1.86(m,2H),1.40-1.34(m,2H),0.93(t,J=7.4 Hz,3H).

[0192] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 436.1867, Actual value: 436.1868.

[0193] compound 53 [ka] (E)-3-Butyl-2-(3-chloro-4-methoxyphenyl)-9-(hydroxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.10(s,1H),8.30(d,J=8.0 Hz,1H),8.16(d,J=7.6 Hz,1H),7.81(s,1H),7.70(d,J=8.4 Hz,2H),7.64(d,J=7.6 Hz,1H),7.34(d,J=8.5 Hz,1H),4.48(t,J=8.4 Hz,2H),3.94(s,3H),1.72-1.67(m,2H),1.19-1.12(m,2H),0.76(t,J=7.4 Hz,3H).

[0194] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 410.1266, Actual value: 410.1266.

[0195] compound 54 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-naphthyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 11H NMR (400 MHz, Chloroform-d) δ 13.83 (s, 1H), 8.50 (dd, J = 7.8, 1.2 Hz, 1H), 8.34 (dd, J = 7.8, 1.6 Hz, 1H), 8.12 (dd, J = 7.2, 2.2 Hz, 1H), 8.01 (dd, J = 8.0, 1.8 Hz, 1H), 7.78 - 7.51 (m, 7H), 4.38 (t, J = 7.4 Hz, 2H), 1.67 (p, J = 7.6 Hz, 2H), 1.13 (h, J = 7.4 Hz, 2H), 0.69 (t, J = 7.4 Hz, 3H).

[0196] HRMS (ESI): m / z calculated value: C 12 H9N3O2 [M + H] + 396.1707, found: 396.1709.

[0197] Compound 55

Chem.

[0198] HRMS (ESI): m / z calculated value: C 12 H9N3O2 [M + H] + 338.1111, found: 338.1115.

[0199] Compound 56

Chem.

[0200] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 336.1343, Actual value: 336.1344.

[0201] compound 57 [ka] (E)-3-Butyl-9-(hydroxyimino)-2-(thiophen-2-yl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,Chloroform-d)δ13.78(s,1H),8.44(d,J=8.0 Hz,1H),8.34-8.13(m,1H),7.70-7.52(m,4H),7.24(s,1H),4.82-4.71(m,2H),1.95(p,J=8.2 Hz,2H),1.53-1.45(m,2H),1.01(t,J=7.4 Hz,3H).

[0202] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 352.1114, Actual value: 352.1116.

[0203] compound 58 [ka] (E)-2-Ethyl-11-(hydroxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.71(s,1H),8.60(d,J=5.6 Hz,2H),8.21-8.15(m,2H),7.71-7.65(m,2H),2.76(q,J=7.6 Hz,2H),1.27(t,J=7.6 Hz,2H),4.09(s,1H).

[0204] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 306.1237, Actual value: 306.1236.

[0205] compound 59 [ka] (E)-2-(furan-2-yl)-11-(hydroxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ13.85(s,1H),8.69(s,2H),8.27-8.22(m,2H),7.95(d,J=1.2 Hz,1H),7.76-7.70(m,2H),7.35(d,J=3.4 Hz,1H),6.75-6.70(m,1H),4.25(s,1H).

[0206] HRMS(ESI): m / z theoretical value: C 12 H9N3O2[M+H] + 344.1030, Actual value: 344.1031.

[0207] Example 6 2,3-Diamino-1,4-benzoquinone (20 g) was dissolved in 100 mL of formic acid, refluxed for 6 hours, cooled to room temperature, poured into ice water mixture, added ammonia water to adjust pH to 9-10, suction filtered, vacuum dried, and obtained 1,4-naphthoquinone imidazole (22 g) as a yellow solid. 1,4-naphthoquinone imidazole (0.3 g) and potassium hydroxide (0.15 g) were added in order to dimethyl sulfoxide solution (3 mL), the mixture was stirred at 50 ° C for 30 minutes, methyl iodide (0.2 mL) was added, reacted for 2 hours, water was added to precipitate a solid, suction filtered, washed with water, and vacuum dried to obtain 2-methyl-1,4-naphthoquinone imidazole (0.31 g) as a yellow solid. 2-Methylnaphthoquinoneimidazole (0.2 g), methoxyamine hydrochloride (0.1 g), and pyridine (0.08 mL) were dissolved in ethanol (30 mL) and reacted at 125°C for 12 hours. After the reaction was completed, a solid was precipitated in the solution, which was directly suction filtered and dried in vacuum to obtain a pale yellow solid (0.15 g).

[0208] 2,3-Diamino-1,4-naphthoquinone (20 g) was dissolved in 100 mL of formic acid and refluxed for 6 hours to obtain anthraquinone imidazole. Compounds 60 to 77 were prepared by the method of Example 6 using different substituted amine oxide hydrochlorides. The materials and reaction conditions of other compounds were unchanged, and the raw materials were all commercially available.

[0209] compound 60 [ka] (E) and (Z)-9-(methoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ8.99(dd,J=8.0,1.2 Hz,1H),8.31-8.20(m,4H),8.16-8.07(m,2H),7.82-7.60(m,5H),4.24(s,3H),4.20(s,4H),4.03(s,4H),3.99(s,3H).

[0210] 13 C NMR(101 MHz,DMSO)δ175.40,174.52,145.91,145.85,145.58,140.34,139.95,139.03,133.69,133.20,133.12,132.39, 131.62,131.20,131.09,129.94,128.10,128.03,127.04,126.43,126.16,124.33,64.73,64.47,34.20,33.92.

[0211] HRMS(ESI): m / z theoretical value: C 13 H 11 N3O2[M+H] + 242.0924, Actual value: 242.0928.

[0212] compound 61 [ka] (E) and (Z)-9-(ethoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.04(dd,J=8.0,1.2 Hz,1H),8.30(dd,J=8.0,1.2 Hz,2H),8.26-8.20(m,3H),8.14-8.07(m,3H),7.79(td,J=8.0,1.6 Hz,1H),7.75-7.68(m,3H),7.63(td,J=8.0,1.2 Hz,2H),4.53-4.42(m,6H),4.04(s,6H),4.00(s,3H),1.46-1.32(m,9H).

[0213] 13C NMR(101 MHz,DMSO)δ175.42,174.53,146.10,145.90,145.64,140.16,139.75,139.33,133.66,133.50,133.04,132.38,131.51 ,131.07,129.79,128.08,128.04,127.00,126.37,126.10,124.33,124.09,72.72,72.20,34.16,33.90,15.29,15.04.

[0214] HRMS(ESI): m / z theoretical value: C 14 H 13 N3O2[M+H] + 256.1081, measured value: 256.1085.

[0215] compound 62 [ka] (E) and (Z)-9-(benzyloxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ8.30-8.22(m,2H),8.11(dd,J=8.0,1.2 Hz,1H),7.71(td,J=8.0,1.6 Hz,1H),7.64(td,J=8.0,1.2 Hz, 1H), 7.55-7.49 (m, 2H), 7.45-7.31 (m, 3H), 5.50 (s, 2H), 4.03 (s, 3H).

[0216] compound 63 [ka] (E) and (Z)-9-(isopropoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR(400 MHz, DMSO-d6)δ9.07(dd,J=8.0,1.2 Hz,1H),8.33(dd,J=8.0,1.2 Hz,1H),8.28-8.21(m,2H),8.16-8.10(m,2H),7.80(td,J=8.0,1.6 Hz,1H),7.72(td,J=8.0,1.4 Hz,2H),7.63(td,J=8.0,1.2 Hz,1H),4.72-4.60(m,2H),4.04(s,3H),4.00(s,3H),1.43(dd,J=12.0,8.0 Hz,12H).

[0217] 13 C NMR(101 MHz, DMSO) δ175.44,174.53,146.27,145.91,145.69,139.80,139.47,139.28,133.77,133.66,133.03,132.39,131.42 ,131.07,130.99,129.68,128.14,128.00,127.00,126.32,126.07,124.33,79.35,78.63,34.16,33.91,22.10,21.97.

[0218] HRMS(ESI):m / z theoretical value:C 15 H 15 N3O2[M+H] + 270.1237, measured value: 270.1238.

[0219] Compound 64

change

[0220] 13 C NMR(101 MHz,DMSO)δ175.45,174.54,146.12,145.96,145.75,140.23,139.79,139.45,133.74,133.53,133.09,132.41,131.42,131.14,129. 82,128.11,128.07,127.07,126.92,126.40,126.14,124.34,76.88,76.36,34.17,33.92,31.53,31.20,19.23,19.08,14.25,14.23.

[0221] HRMS(ESI): m / z theoretical value: C 16 H 17 N3O2[M+H] + 284.1394, Actual value: 284.1398.

[0222] compound 65 [ka] (E) and (Z)-9-(isobutoxyimino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR(400 MHz, DMSO-d6)δ9.04(dd,J=8.1,1.2 Hz,1H),8.33-8.23(m,4H),8.15-8.09(m,3H),7.82(td,J=8.0,1.6 Hz,1H),7.75-7.69(m,2H),7.64(td,J=8.0,1.2 Hz,2H),4.25(d,J=8.0 Hz,2H),4.21(d,J=8.0 Hz,3H),4.04(s,5H),4.00(s,3H),2.20-2.09(m,3H),1.01(t,J=6.0 Hz,16H).

[0223] 13 C NMR(101 MHz, DMSO) δ175.44,174.52,146.10,145.95,145.77,140.24,139.84,139.48,133.73,133.50,133.07,132.42,131.34,1 31.14,131.10,129.80,128.08,127.09,126.40,126.13,124.32,83.43,82.87,34.16,33.92,28.50,28.21,19.45,19.42.

[0224] HRMS(ESI):m / z theoretical value:C 16 H 17 N3O2[M+H] + 284.1394, measured value: 284.1397.

[0225] Compound 66

change

[0226] 13 C NMR(101 MHz,DMSO)δ175.47,174.56,146.58,145.91,145.70,139.61,139.39,138.81,134.17,133.61,133.01,132.40,131.32 ,131.05,130.83,129.52,128.22,127.95,126.95,126.23,126.02,124.29,82.90,82.08,34.15,33.90,28.02,27.74.

[0227] HRMS(ESI): m / z theoretical value: C 16 H 17 N3O2[M+H] + 284.1394, Actual value: 284.1393.

[0228] compound 67 [ka] (E) and (Z)-9-((cyclopropyloxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.10(dd,J=8.0,1.2 Hz,1H),8.33-8.24(m,4H),8.16- 8.09(m,3H),7.84-7.77(m,1H),7.75-7.70(m,2H),7.64(td,J=8.0,1.2 Hz,2H),4.32-4.24(m,5H),4.04(s,5H),4.00(s,3H),1.36-1.26(m,3H),0.65-0.55(m,6H),0.48-0.35(m,5H).

[0229] 13 C NMR(101 MHz,DMSO)δ175.45,174.54,146.15,145.95,145.72,140.08,139.62,139.41,133.69,133.58,133.07,132.40,131.50,131. 11,131.09,129.77,128.17,128.06,127.04,126.39,126.12,124.35,81.62,80.98,34.16,33.91,11.04,10.65,3.64,3.59.

[0230] HRMS(ESI): m / z theoretical value: C 16 H 15 N3O2[M+H] + 282.1237, Actual value: 282.1238.

[0231] compound 68 [ka] (E) and (Z)-9-((allyloxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.03(dd,J=8.0,1.2 Hz,1H),8.30-8.21(m,6H),8.15-8.08(m,4H),7.80(td,J=8.0,1.6 Hz,1H),7.77-7.65(m,4H),7.64(td,J=8.0,1.2 Hz,3H),6.22-6.08(m,4H),5.55-5.40(m,4H),5.36-5.27(m,4H),5.00-4.92(m,7H),4.04(s,8H),3.99(s,3H).

[0232] 13C NMR(101 MHz,DMSO)δ175.43,174.51,145.94,145.72,140.65,140.24,139.31,135.14,134.58,134.13,133.71,133.34,133.09,132.42, 131.59,131.22,131.12,129.93,128.15,128.05,127.08,126.48,126.15,124.37,119.04,118.54,77.72,77.22,34.16,33.92.

[0233] HRMS(ESI): m / z theoretical value: C 15 H 13 N3O2[M+H] + 268.1081, Actual value: 268.1083.

[0234] compound 69 [ka] (E) and (Z)-3-Methyl-9-(((4-methoxybenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.05-8.98(m,1H),8.34-8.27(m,3H),8.27-8.20(m,4H),8.15-8.09(m,4H),7.76-7.61(m,8H),7. 49-7.43(m,8H),6.99-6.93(m,8H),5.44(s,2H),5.41(s,6H),4.03(s,9H),3.99(s,3H),3.76(s,3H),3.75(s,9H).

[0235] 13C NMR(101 MHz,DMSO)δ175.43,174.52,159.81,159.60,145.98,145.75,140.52,140 .16,139.34,133.72,133.41,133.13,132.42,131.50,131.19,131.13,13 0.65,130.54,129.93,129.82,129.17,128.15,128.09,127.08,126.48,1 26.16,124.38,114.40,114.24,78.57,78.04,55.58,55.55,34.16,33.92.

[0236] HRMS(ESI): m / z theoretical value: C 20 H 17 N3O3[M+H] + 348.1343, Actual value: 348.1339.

[0237] compound 70 [ka] (E) and (Z)-3-Methyl-9-(((4-chlorobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.03(dd,J=8.0,1.2 Hz,1H),8.28-8.22(m,5H),8.14-8.08(m,3H),7.82-7.60(m,7H),7.57-7.43(m,13H),5.51(s,2H),5.49(s,4H),4.03(s,6H),3.99(s,3H).

[0238] 13C NMR(101 MHz,DMSO)δ175.42,174.50,145.97,145.80,140.99,140.68,139.26,13 7.10,136.54,133.77,133.30,133.21,133.16,132.98,132.47,131.63, 131.33,131.31,131.16,130.52,130.32,130.06,129.03,128.87,128.2 7,128.03,127.13,126.55,126.20,124.40,77.67,77.17,34.17,33.92.

[0239] HRMS(ESI): m / z theoretical value: C 19 H 14 ClN3O2[M+H] + 352.0847, Actual value: 352.0843.

[0240] compound 71 [ka] (E) and (Z)-3-Methyl-9-(((4-trifluoromethylbenzyl)oxy)imino))-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one Yellow solid, 100 mg, % yield, melting point: 136-138°C.

[0241] 1 H NMR(400 MHz,DMSO-d6)δ9.07(dd,J=8.0,1.2 Hz,1H),8.28-8.21(m,4H),8.14-8.07(m,3H),7.82-7.60(m,17H),5.63(s,2H),5.60(s,3H),4.04(s,5H),3.99(s,3H).

[0242] 13C NMR(101 MHz,DMSO)δ175.40,174.48,145.95,145.80,145.73,142.98,142.48,141.24,140.95, 139.23,133.78,133.15,133.11,132.48,131.70,131.35,131.16,130.09,128.94,128 .74, 128.62, 128.31, 128.00, 127.13, 126.57, 126.19, 126.07, 125.95, 125.91, 125.87, 125.83, 125.79, 125.76, 125.72, 125.68, 124.39, 123.37, 77.49, 77.04, 34.17, 33.90.

[0243] HRMS(ESI): m / z theoretical value: C 20 H 14 F3N3O2[M+H] + 386.1111, Actual value: 386.1107.

[0244] compound 72 [ka] (E) and (Z)-3-Methyl-9-(((4-fluorobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.03(dd,J=8.0,1.4 Hz,1H),8.33-8.20(m,5H),8.18-8.09(m,3H),7.79-7.53(m,12H),7.30-7.17(m,7H),5.50(s,2H),5.48(s,3H),4.03(s,5H),3.99(s,3H).

[0245] 13C NMR(101 MHz,DMSO)δ175.43,174.51,163.71,163.54,161.12,145.98,145.88,145.79,140.85,14 0.53,139.28,134.26,134.23,133.76,133.72,133.69,133.27,133.16,132.46,131.59, 131.28, 131.16, 131.06, 130.98, 130.84, 130.76, 130.03, 129.51, 128.24, 128.04, 127.12, 126.54, 126.19, 124.40, 115.96, 115.79, 115.75, 115.57, 77.83, 77.35, 34.17, 33.92.

[0246] HRMS(ESI): m / z theoretical value: C 19 H 14 FN3O2[M+H] + 336.1143, Actual value: 336.1140.

[0247] compound 73 [ka] (E) and (Z)-3-Methyl-9-(((perfluorobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one Yellow solid, 100 mg, % yield, melting point: 224-226°C.

[0248] 1 H NMR(400 MHz,DMSO-d6)δ8.92(dd,J=8.0,1.2 Hz,1H),8.26-8.07(m,7H),7.83-7.71(m,4H),7.65(td,J=8.0,1.2 Hz, 2H), 5.61 (s, 2H), 5.53 (s, 3H), 4.02 (s, 5H), 3.98 (s, 3H).

[0249] 13C NMR(101 MHz,DMSO)δ175.39,174.49,146.06,145.82,145.43,144.63,141.75,141.24,138.94,133.86,133.81,133.32,132.90,132.55,131.67, 131.67,131.59,131.23,130.34,130.11,128.49,128.46,127.93,127.87,127.20,126.26,124.69,124.25,65.48,64.75,34.17,33.93.

[0250] HRMS(ESI): m / z theoretical value: C 19 H 10 F5N3O2[M+H] + 408.0766, Actual value: 408.0767.

[0251] compound 74 [ka] (E) and (Z)-3-Methyl-9-(((4-nitrobenzyl)oxy)imino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.09(dd,J=8.0,1.2 Hz,1H),8.31-8.17(m,14H),8.13-8.09(m,3H),7.84-7.62(m,15H),5.67(s,2H),5.65(s,5H),4.08-4.02(m,8H),3.99-3.97(m,3H).

[0252] 13C NMR(101 MHz,DMSO)δ175.42,174.50,147.64,147.47,146.09,145.97,145.85,14 5.66,145.55,141.45,141.20,139.20,133.85,133.21,133.02,132.51, 131.79,131.46,131.18,130.20,129.18,128.95,128.37,127.98,127.1 9,126.62,126.24,124.43,124.15,124.03,77.09,76.65,34.20,33.93.

[0253] HRMS(ESI): m / z theoretical value: C 19 H 14 N4O4[M+H] + 363.1088, Actual value: 363.1084.

[0254] compound 75 [ka] (E) and (Z)-11-(benzyloxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.67(s,1H),8.79(d,J=6.8 Hz,2H),8.73(s,1H),8.27(s,1H),8.23-8.08(m,6H),8.00-7.95(m,1H),7.73-7.5 5(m,11H),7.46-7.33(m,8H),5.57(s,2H),5.53(s,3H),4.06(s,5H),4.01(s,3H).

[0255] HRMS(ESI): m / z theoretical value: C 19 H 14 N4O4[M+H] + 368.1394, Actual value: 368.1397.

[0256] compound 76 [ka] (E) and (Z)-11-(butoxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.58(s,1H),8.75(d,J=2.1 Hz,2H),8.69(s,1H),8.24(s,1H),8.21-8.09(m,5H),8.02-7.98(m,1H),7.73-7.59(m,5H),4.45(dt,J=20.6,6.6 Hz,5H),4.05(s,3H),4.01(s,4H),1.90-1.75(m,5H),1.57-1.45(m,5H),1.05-0.96(m,7H).

[0257] HRMS(ESI): m / z theoretical value: C 19 H 14 N4O4[M+H] + 334.2210, Actual value: 334.2214.

[0258] compound 77 [ka] (E) and (Z)-11-(tert-butoxyimino)-3-methyl-3,11-dihydro-4H-anthraquinone[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.70(s,1H),8.87(s,1H),8.81(s,1H),8.74(s,1H),8.28-8.13(m,5H),8 .07-8.02(m,1H),7.75-7.60(m,4H),4.08(s,3H),4.04(s,3H),1.55(s,9H),1.52(s,9H).

[0259] HRMS(ESI): m / z theoretical value: C 19 H 14 N4O4[M+H] + 334.2210, Actual value: 334.2213.

[0260] Example 7 2,3-Diamino-1,4-benzoquinone (20 g) was dissolved in 100 mL of formic acid, refluxed for 6 hours, cooled to room temperature, poured into ice water mixture, added ammonia water to adjust pH to 9-10, suction filtered, vacuum dried, and obtained 1,4-naphthoquinone imidazole (22 g) as a yellow solid. 1,4-naphthoquinone imidazole (0.3 g) and potassium hydroxide (0.15 g) were added in order to dimethyl sulfoxide solution (3 mL), the mixture was stirred at 50 ° C for 30 minutes, methyl iodide (0.2 mL) was added, reacted for 2 hours, water was added to precipitate a solid, suction filtered, washed with water, and vacuum dried to obtain 2-methyl-1,4-naphthoquinone imidazole (0.31 g) as a yellow solid. 2-Methylnaphthoquinoneimidazole (0.2 g), hydroxylamine hydrochloride (0.3 g), and pyridine (0.7 mL) were dissolved in ethanol (70 mL) and reacted at 105 ° C for 36 hours. After the reaction was completed, a solid was precipitated in the solution, directly suction filtered, and dried in vacuum to obtain a pale yellow solid (E)-9-(hydroxyimino)-3-methyl-3,6,7,9-tetrahydro-4H-naphtho[2,3-d]imidazol-4-one (0.15 g). 106 mg of the oxime-modified product was added to 2 mL of dimethyl sulfoxide solution, then 56 μL of bromomethyl ethyl ether and 104 mg of potassium hydroxide were added in sequence, and the reaction was allowed to proceed at room temperature for 2 hours. After the reaction was completed, the mixture was quenched by adding water, extracted with dichloromethane, and the organic phase was washed with saturated saline, dried over anhydrous magnesium sulfate, concentrated, and then separated by silica gel column chromatography.

[0261] The oxime-formed product can be reacted with different substituted halogenated hydrocarbons to produce compounds 78-82 according to the method of Example 7. The materials and reaction conditions for other compounds are the same, and the raw materials are all commercially available.

[0262] compound 78 [ka] (E)-9-((2-methoxyethoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ8.34-8.24(m,2H),8.16-8.09(m,1H),7.76-7.70(m,1H),7.65(td,J=8.0,1.2 Hz,1H),4.53(t,J=4.0 Hz,2H),4.04(s,3H),3.76(t,J=4.0 Hz,2H),3.32(s,3H).

[0263] 13 C NMR (101 MHz, DMSO) δ175.46,145.74,140.04,139.32,133.40,133.14,131.13,129.95,128.15,126.17,124.43,76.07,70.75,58.76,34.18.

[0264] HRMS(ESI): m / z theoretical value: C 15 H 15 N3O3[M+H] + 286.1186, Actual value: 286.1188.

[0265] compound 79 [ka] (E) and (Z)-9-((2-(benzyloxy)ethoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ8.30-8.25(m,2H),8.15-8.10(m,1H),7.75-7.61(m,2H),7.38-7. 31(m,2H),7.30-7.21(m,3H),4.63-4.54(m,4H),4.04(s,3H),3.89-3.82(m,2H).

[0266] 1313C NMR (101 MHz, DMSO-d6) δ 175.45, 145.72, 140.12, 139.36, 138.95, 133.39, 133.08, 131.13, 129.92, 128.60, 128.15, 127.86, 127.74, 126.14, 124.43, 76.28, 72.40, 68.47, 34.18.

[0267] HRMS (ESI): calculated m / z for C 21 H 19 N3O3 [M + H] + 362.1499, found 362.1495.

[0268] Compound 80

Chem.

[0269] 13 13C NMR (101 MHz, DMSO-d6) δ 175.45, 145.72, 140.07, 139.31, 133.40, 133.13, 131.13, 129.95, 128.15, 126.16, 124.45, 76.25, 71.78, 70.26, 69.26, 58.52, 34.18.

[0270] HRMS (ESI): calculated m / z for C 17 H 19 N3O4 [M + H]+ 330.1448, Actual value: 330.1447.

[0271] compound 81 [ka] (E) and (Z)-9-((2-(2-(2-methoxyethoxy)ethoxy)ethoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ8.30(dd,J=8.0,1.2 Hz,1H),8.23(s,1H),8.14-8.10(m,1H),7.74-7.69(m,1H),7.65(td,J=8.0,1.2 Hz,1H),4.55-4.51(m,2H),4.04(s,3H),3.87-3.82(m,2H),3.65-3.59(m,2H),3.54-3.47(m,4H),3.39-3.35(m,2H),3.19(s,3H).

[0272] 13 C NMR(101 MHz,DMSO-d6)δ175.44,145.70,140.04,139.29,133.39,133.11,131.10,129.93, 128.12,126.14,124.43,76.23,71.70,70.48,70.24,70.03,69.26,58.46,34.16.

[0273] HRMS(ESI): m / z theoretical value: C 19 H 23 N3O5[M+H] + 374.1710, Actual value: 374.1709.

[0274] compound 82 [ka] (E)-9-((3-aminopropoxy)imino)-3-methyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR(400 MHz,DMSO-d6)δ8.30-8.25(m,2H),8.15-8.10(m,1H),7.75-7.61(m,2H),4.04(s,3H),3.51(t,J=8.0 Hz,2H),2.68(t,J=8.0 Hz,2H),1.79-1.70(m,2H).

[0275] HRMS(ESI): m / z theoretical value: C 19 H 23 N3O5[M+H] + 285.1346, Actual value: 285.1347.

[0276] Example 8 2,3-Diamino-1,4-benzoquinone (20 g) was dissolved in 100 mL of formic acid, refluxed for 6 hours, cooled to room temperature, poured into ice water mixture, added ammonia water to adjust the pH to 9-10, suction filtered, vacuum dried, and obtained 1,4-naphthoquinone imidazole (22 g) as a yellow solid. 1,4-naphthoquinone imidazole (0.3 g) and potassium hydroxide (0.15 g) were added in order to dimethyl sulfoxide solution (3 mL), the mixture was stirred at 50 ° C for 30 minutes, butyl iodide (0.18 mL) was added, reacted for 5 hours, water was added to precipitate the solid, suction filtered, washed with water, and vacuum dried to obtain 2-butyl-1,4-naphthoquinone imidazole (0.31 g) as a yellow solid. 2-Butylnaphthoquinone imidazole (0.21 g), methoxyamine hydrochloride (0.3 g), and pyridine (0.7 mL) were dissolved in ethanol (70 mL) and reacted at 105° C. for 36 hours. After the reaction was completed, the mixture was concentrated and separated using a silica gel chromatography column to obtain a pale yellow product (0.18 g).

[0277] 2,3-Diamino-1,4-naphthoquinone (20 g) is dissolved in 100 mL of formic acid, and the mixture is refluxed for 6 hours to obtain anthraquinone imidazole. Compounds 83 to 86 can be prepared by the method of Example 8 using different substituted halogenated hydrocarbons or different substituted amineoxy hydrochlorides. The materials and reaction conditions of other compounds are the same, and the raw materials are all commercially available.

[0278] compound 83 [ka] (E) and (Z)-3-Butyl-9-(methoxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1 H NMR(400 MHz,DMSO-d6)δ9.00(dd,J=8.0,1.2 Hz,1H),8.34-8.21(m,4H),8.13(dd,J=8.0,1.4 Hz,1H),7.82-7.62(m,4H),4.46(t,J=7.2 Hz,2H),4.40(t,J=7.0 Hz,2H),4.24(s,3H),4.21(s,3H),1.84-1.72(m,4H),1.37-1.18(m,4H),0.91(t,J=8.0 Hz,6H).

[0279] 13 C NMR(101 MHz,DMSO)δ175.14,174.26,146.33,145.50,145.23,140.43,140.02,139.65,133.69,133.17,133.10,132.43,131.59,131.2 0,131.15,129.93,127.94,127.51,127.14,126.25,125.85,124.31,64.75,64.49,46.53,46.39,32.75,19.52,19.50,13.88.

[0280] HRMS(ESI): m / z theoretical value: C 16 H 17 N3O2[M+H] + 284.1394, Actual value: 284.1394.

[0281] compound 84 [ka] (E) and (Z)-3-Butyl-9-(ethoxyimino)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR(400 MHz,DMSO-d6)δ9.06(d,J=8.0 Hz,1H),8.37-8.19(m,6H),8.14(d,J=8.0 Hz,2H),7.83-7.61(m,6H),4.55-4.36(m,11H),1.82-1.72(m,6H),1.46-1.38(m,9H),1.35-1.20(m,7H),0.91(t,J=8.0 Hz,9H).

[0282] 13 C NMR(101 MHz,DMSO)δ175.16,174.27,146.52,145.50,145.27,140.23,139.77,133.69,133.43,133.07,132.42,131.50,131.13,129. 82,128.00,127.43,127.13,126.21,125.79,124.31,72.74,72.25,46.52,46.38,32.78,19.52,19.50,15.29,15.06,13.89.

[0283] HRMS(ESI): m / z theoretical value: C 17 H 19 N3O2[M+H] + 298.1550, Actual value: 298.1549.

[0284] compound 85 [ka] (E) and (Z)-9-((benzyloxy)imino)-3-butyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 1H NMR(400 MHz, DMSO-d6)δ9.06(dd,J=8.0,1.2 Hz,1H),8.36-8.24(m,6H),8.22(s,1H),8.13(dd,J=8.0,1.6 Hz,2H),7.81-7.69(m,4H),7.65(dd,J=8.0,1.4 Hz,2H),7.63-7.59(m,1H),7.56-7.49(m,6H),7.45-7.31(m,16H),5.53(s,2H),5.50(s,5H),4.45(t,J=7.2 Hz,5H),4.39(t,J=7.1 Hz,2H),1.82-1.72(m,7H),1.34-1.22(m,7H),0.90(td,J=8.0,1.0 Hz,11H).

[0285] Compound 86

change

[0286] HRMS(ESI):m / z theoretical value:C 17 H 19 N3O2[M+H] + 380.1605, measured value: 380.1609.

[0287] (Example 9) 2,3-Diamino-1,4-benzoquinone (20 g) was dissolved in 100 mL of acetic acid, refluxed for 6 hours, cooled to room temperature, poured into ice water mixture, ammonia water was added to adjust the pH to 9-10, suction filtered, and vacuum dried to obtain yellow solid 1,4-naphthoquinone imidazole (22 g). 1,4-naphthoquinone imidazole (0.3 g) and potassium hydroxide (0.15 g) were added in sequence to dimethyl sulfoxide solution (3 mL), the mixture was stirred at 50 ° C for 30 minutes, butyl iodide (0.18 mL) was added, reacted for 5 hours, water was added to precipitate the solid, suction filtered, washed with water, and vacuum dried to obtain yellow solid 2-butyl-1,4-naphthoquinone imidazole (0.31 g). 2-Butylnaphthoquinone imidazole (0.21 g), methoxyamine hydrochloride (0.3 g), and pyridine (0.7 mL) were dissolved in ethanol (70 mL) and reacted at 105° C. for 36 hours. After the reaction was completed, the mixture was concentrated and separated using a silica gel chromatography column to obtain a pale yellow product (0.16 g).

[0288] 2,3-Diamino-1,4-naphthoquinone (20g) was dissolved in 100mL of formic acid, and the mixture was refluxed for 6 hours to obtain anthraquinone imidazole. Compounds 87-88 were prepared by the method of Example 9. The materials and reaction conditions of other compounds were the same, and the raw materials were all commercially available.

[0289] compound 87 [ka] (E) and (Z)-9-((benzyloxy)imino)-2,3-dimethyl-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 11H NMR (400 MHz, DMSO-d6) δ 8.99 (dd, J = 8.0, 1.4 Hz, 1H), 8.22 - 8.16 (m, 4H), 8.05 (dd, J = 7.8, 1.6 Hz, 3H), 7.73 - 7.68 (m, 1H), 7.66 - 7.62 (m, 3H), 7.58 (td, J = 7.6, 1.4 Hz, 3H), 7.51 - 7.45 (m, 7H), 7.39 - 7.31 (m, 8H), 7.31 - 7.26 (m, 3H), 5.48 (s, 2H), 5.46 (s, 5H), 3.93 (s, 8H), 3.87 (s, 3H), 2.45 (s, 8H), 2.40 (s, 3H).

[0290] HRMS (ESI): m / z Theoretical value: C 17 H 19 N3O2 [M+H] + 332.1394, Measured value: 332.1398.

[0291] Compound 88

Chemical Structure

[0292] HRMS (ESI): m / z Theoretical value: C 17 H 19 N3O2 [M+H] + 382.1550, Measured value: 382.1558.

[0293] (Example 10) 2,3-Diamino-1,4-benzoquinone (4 g) was dissolved in 13 mL of dimethyl sulfoxide, 3,4,5-trimethoxybenzaldehyde (2.5 mL) was added, and the mixture was reacted at 80°C for 13 hours with the lid open. After cooling to room temperature, water was slowly added to precipitate a solid, which was then suction filtered and vacuum dried to obtain a yellow solid, 2-(3,4,5-trimethoxyphenyl)-1,4-naphthoquinone imidazole (0.15 g). Naphthoquinone imidazole (0.4g) and potassium hydroxide (0.15g) were added in order to a dimethyl sulfoxide solution (3mL), the mixture was stirred at 50℃ for 30 minutes, butyl iodide (0.17mL) was added, and the mixture was reacted for 5 hours. Water was added to precipitate the solid, which was then suction filtered, washed with water, and dried in vacuum to obtain a yellow solid, 1-butyl-2-(3,4,5-trimethoxyphenyl)-1,4-naphthoquinone imidazole (0.35g). Naphthoquinone imidazole (0.42g), benzyloxyamine hydrochloride (0.64g), and pyridine (0.7mL) were dissolved in ethanol (70mL), reacted at 105℃ for 36 hours, and concentrated after the reaction was completed, and separated by a silica gel chromatography column to obtain a pale yellow product (0.36g).

[0294] 2,3-Diamino-1,4-naphthoquinone (4 g) is dissolved in 13 mL of dimethyl sulfoxide, and reacted with different aldehydes or with different substituted amine hydrochlorides to prepare compounds 89 to 90 according to the method of Example 10. The materials and reaction conditions of other compounds are the same, and the raw materials are all commercially available.

[0295] compound 89 [ka] (E) and (Z)-9-((benzyloxy)imino)-3-butyl-2-(3,4,5-trimethoxyphenyl)-3,9-dihydro-4H-naphtho[2,3-d]imidazol-4-one 11H NMR (400 MHz, DMSO-d6) δ 9.04 (d, J = 8.0 Hz, 1H), 8.27 (t, J = 7.0 Hz, 2H), 8.13 (dd, J = 7.8, 1.6 Hz, 2H), 7.72 (dt, J = 15.2, 7.4 Hz, 3H), 7.63 (t, J = 7.6 Hz, 2H), 7.57 - 7.50 (m, 3H), 7.47 (d, J = 7.4 Hz, 2H), 7.40 - 7.18 (m, 14H), 6.98 (s, 3H), 6.95 (s, 2H), 5.52 (s, 2H), 5.48 (s, 3H), 4.53 (s, 3H), 4.47 (t, J = 7.4 Hz, 3H), 4.41 (t, J = 7.6 Hz, 2H), 3.82 (s, 4H), 3.80 (s, 7H), 3.72 (d, J = 1.2 Hz, 5H), 1.70 - 1.65 (m, 5H), 1.21 - 1.15 (m, 5H), 0.85 - 0.70 (m, 7H).

[0296] HRMS (ESI): m / z calculated value: C 17 H 19 N3O2 [M + H] + 526.2337, found value: 526.2337.

[0297] Compound 90

Chemical formula

[0298] HRMS (ESI): m / z calculated value: C 17 H 19 N3O2 [M + H] + 332.1394, found value: 332.1395.

[0299] Example 11 Compound 1 (0.05 mmol) was added to 3 mL of acetonitrile and 31 μL of methyl iodide, and reacted for 24 hours at 120° C. After the reaction was completed, the solvent was removed to obtain a yellow solid, which was slurried for half an hour and then suction filtered to obtain the final product.

[0300] Using the above different synthetic intermediate compounds, compounds 91 to 118 can be prepared by the method of Example 11. The materials and reaction conditions of other compounds are unchanged, and the raw materials are all commercially available.

[0301] compound 91 [ka] (E)-1-Methyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.50(s,1H),9.57(s,1H),9.25(dd,J=10.0,0.5 Hz,1H),8.33(dd,J=10.0,1.0 Hz,1H),8.01-7.93(m,1H),7.85(td,J=5.0,1.5 Hz,1H),4.19(s,3H),4.10(s,3H).

[0302] 13 C NMR (126 MHz, DMSO-d6) δ174.28,143.85,138.38,135.34,135.31,131.90,131.49,130.83,127.34,127.16,125.39,38.98,36.41.

[0303] HRMS (ESI-TOF): m / z theoretical value: C 13 H 12 N3O2[MI] + 242.0924, Actual value: 242.0928.

[0304] compound 92 [ka] (E)-1-Ethyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.49(s,1H),9.67(s,1H),9.26(dd,J=10.0,1.0 Hz,1H),8.34(dd,J=10.0,1.0 Hz,1H),7.96(td,J=10.0,1.5 Hz,1H),7.85(td,J=10.0,1.0 Hz,1H),4.63(q,J=7.5 Hz,2H),4.11(s,3H),1.53(t,J=5.0 Hz,3H).

[0305] 13 C NMR (126 MHz, DMSO-d6) δ174.01,143.12,138.52,135.86,135.28,131.83,131.37,130.85,127.39,127.03,124.77,44.93,39.09,15.42.

[0306] HRMS (ESI-TOF): m / z theoretical value: C 14 H 14 N3O2[MI] + 256.1081, Actual value: 256.1078.

[0307] compound 93 [ka] (E)-4-(Hydroxyimino)-3-methyl-9-oxo-1-propyl-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 11H NMR (500 MHz, DMSO-d6) δ 14.51 (s, 1H), 9.67 (s, 1H), 9.25 (dd, J = 10.0, 1.0 Hz, 1H), 8.34 (dd, J = 10.0, 1.5 Hz, 1H), 8.00 - 7.93 (m, 1H), 7.85 (td, J = 10.0, 1.0 Hz, 1H), 4.57 (t, J = 7.0 Hz, 2H), 4.11 (s, 3H), 1.96 - 1.85 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H).

[0308] 13 13C NMR (126 MHz, DMSO-d6) δ 174.09, 143.40, 138.51, 135.95, 135.29, 131.88, 131.43, 130.91, 127.42, 127.08, 124.84, 50.68, 39.17, 23.13, 10.92.

[0309] HRMS (ESI-TOF): m / z theoretical value: C 15 H 16 N3O2 [M - I] + 270.1237, found: 270.1244.

[0310] Compound 94

Chem.

[0311] 13 C NMR(126 MHz,DMSO-d6)δ174.06,143.37,138.52,135.93,135.28,131.85,131.40,130.89,127.42,127.06,124.80,49.00,39.16,31.69,19.28,13.86.

[0312] HRMS (ESI-TOF): m / z theoretical value: C 16 H 18 N3O2[MI] + 284.1394, Actual value: 284.1393.

[0313] compound 95 [ka] (E)-4-(Hydroxyimino)-1-isopropyl-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ14.50(s,1H),9.81(s,1H),9.24(dd,J=8.0,1.2 Hz,1H),8.35(dd,J=8.0,1.6 Hz,1H),8.04-7.90(m,1H),7.85(td,J=8.0,1.2 Hz,1H),5.49-5.40(m,1H),4.11(s,3H),1.61(d,J=8.0 Hz,6H).

[0314] 13 C NMR (101 MHz, DMSO-d6) δ174.04,141.76,138.52,135.96,135.23,131.88,131.36,131.04,127.51,126.85,124.69,52.90,39.23,22.54.

[0315] HRMS (ESI-TOF): m / z theoretical value: C 15 H 16 N3O2[MI] + 270.12374, Actual value: 270.1237.

[0316] compound 96 [ka] (E)-4-(Hydroxyimino)-1-isobutyl-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.51(s,1H),9.68(s,1H),9.25(dd,J=10.0,0.5 Hz,1H),8.33(dd,J=10.0,1.0 Hz,1H),7.99-7.93(m,1H),7.85(td,J=10.0,1.0 Hz,1H),4.44(d,J=10.0 Hz,2H),4.12(s,3H),2.27-2.10(m,1H),0.98(d,J=5.0 Hz,6H).

[0317] 13 C NMR(126 MHz,DMSO-d6)δ174.14,143.52,138.52,136.06,135.31,131.87,131.41,130.92,127.42,127.08,124.84,55.59,39.26,29.14,19.66.

[0318] HRMS (ESI-TOF): m / z theoretical value: C 16 H 18 N3O2[MI] + 284.1394, Actual value: 284.1387.

[0319] compound 97 [ka] (E)-4-(Hydroxyimino)-3-methyl-1-(2-methylbutyl)-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1H NMR(400 MHz,DMSO-d6)δ14.50(s,1H),9.69(s,1H),9.25(dd,J=8.0,0.8 Hz,1H),8.33(dd,J=8.0,1.4 Hz,1H),8.01-7.91(m,1H),7.84(td,J=8.0,1.2 Hz,1H),4.56(dd,J=12.0,4.0 Hz,1H),4.42-4.35(m,1H),4.12(s,3H),2.07-1.90(m,1H),1.53-1.40(m,1H),1.33-1.19(m,1H),1.00-0.87(m,6H).

[0320] 13 C NMR(101 MHz,DMSO-d6)δ174.12,143.58,138.52,136.06,135.29,131.86,131.40,1 30.91,127.43,127.07,124.87,54.38,39.27,35.19,26.25,16.46,11.30.

[0321] HRMS (ESI-TOF): m / z theoretical value: C 17 H 20 N3O2[MI] + 298.1550, Actual value: 298.1551.

[0322] compound 98 [ka] (E)-1-(tert-Butyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ14.50(s,1H),9.67(s,1H),9.19(dd,J=8.0,1.2 Hz,1H),8.38(dd,J=8.0,1.4 Hz, 1H), 7.98-7.91 (m, 1H), 7.89-7.79 (m, 1H), 4.11 (s, 3H), 1.81 (s, 9H).

[0323] 13C NMR(101 MHz,DMSO-d6)δ173.08,142.92,138.84,138.42,134.98,131.90,131.45,130.93,1210.06,126.24,126.02,63.89,36.40,28.72.

[0324] HRMS (ESI-TOF): m / z theoretical value: C 16 H 18 N3O2[MI] + 284.1394, Actual value: 284.1395.

[0325] compound 99 [ka] (E)-1-Cyclopropyl-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.48(s,1H),9.73(s,1H),9.31-9.16(m,1H),8.35(dd,J=10.0,1.5 Hz,1H),7.96(td,J=10.0,1.0 Hz, 1H), 7.86 (td, J=10.0, 1.0 Hz, 1H), 4.16-4.05 (m, 1H), 4.06 (s, 3H), 1.31-1.18 (m, 4H).

[0326] 13 C NMR (126 MHz, DMSO-d6) δ173.42,143.46,138.43,135.56,135.19,131.93,131.43,131.00,127.40,126.93,126.42,39.02,31.83,7.48.

[0327] HRMS (ESI-TOF): m / z theoretical value: C 15 H 14 N3O2[MI] + 268.1081, Actual value: 268.1081.

[0328] compound 100 [ka] (E)-4-(Hydroxyimino)-1-(2-methoxyethyl)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.51(s,1H),9.65(s,1H),9.25(d,J=10.0,1H),8.33(dd,J=10.0,1.5 Hz,1H),7.97(td,J=10.0,1.5 Hz,1H),7.85(td,J=10.0,1.0 Hz,1H),4.81(t,J=5.0 Hz,2H),4.14(s,3H),3.81(t,J=5.0 Hz,2H),3.30(s,3H).

[0329] 13 C NMR(126 MHz,DMSO-d6)δ174.24,143.67,138.44,135.78,135.33,131.86,131.44,130.88,127.41,127.09,124.77,69.37,58.66,48.91,39.15.

[0330] HRMS (ESI-TOF): m / z theoretical value: C 15 H 16 N3O3[MI] + 286.1186, Actual value: 286.1187.

[0331] Compound 101 [ka] (E)-4-(Hydroxyimino)-3-methyl-1-(3-methyl-2-en-1-yl)-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 11H NMR (500 MHz, DMSO-d6) δ 14.50 (s, 1H), 9.62 (s, 1H), 9.25 (dd, J = 10.0, 1.0 Hz, 1H), 8.34 (dd, J = 10.0, 1.5 Hz, 1H), 7.96 (td, J = 10.0, 1.5 Hz, 1H), 7.85 (td, J = 10.0, 1.0 Hz, 1H), 5.55 - 5.45 (m, 1H), 5.22 (d, J = 5.0 Hz, 2H), 4.11 (s, 3H), 1.84 (s, 3H), 1.80 (s, 3H).

[0332] 13 13C NMR (126 MHz, DMSO-d6) δ 174.14, 142.89, 141.39, 138.44, 135.86, 135.31, 131.89, 131.45, 130.86, 127.42, 127.07, 124.81, 116.94, 47.08, 39.11, 26.02, 18.66.

[0333] HRMS (ESI-TOF): m / z theoretical value: C 17 H 18 N3O2[M - I] + 296.1394, measured value: 296.1390.

[0334] Compound 102

Chemical Structure

[0335] 13C NMR(126 MHz,DMSO-d6)δ174.00,143.75,138.46,136.14,135.37,134.74,131.87,131 .44,130.76,129.34,129.11,128.56,127.39,127.12,124.57,51.80,39.35.

[0336] HRMS (ESI-TOF): m / z theoretical value: C 19 H 16 N3O2[MI] + 318.1237, Actual value: 318.1233.

[0337] compound 103 [ka] (E)-1-(2-ethoxy-2-oxoethyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.62(s,1H),9.61(s,1H),9.27(d,J=10.0 Hz,1H),8.30(dd,J=10.0,1.5 Hz,1H),7.99(td,J=10.0,1.5 Hz,1H),7.88-7.82(m,1H),5.58(s,2H),4.26(q,J=7.0 Hz,2H),4.19(s,3H),1.27(t,J=7.0 Hz,3H).

[0338] 13 C NMR(126 MHz,DMSO-d6)δ174.04,166.57,144.24,138.22,135.63,135.54,131.97,131.59,130.42,127.36,127.23,124.83,62.54,49.97,39.38,14.51.

[0339] HRMS (ESI-TOF): m / z theoretical value: C 16 H 16 N3O4[MI] +314.1135, Actual value: 314.1138.

[0340] Compound 104 [ka] (E)-4-(Hydroxyimino)-3-methyl-9-oxo-1-phenyl-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.60(s,1H),10.00(s,1H),9.28(d,J=5.0,Hz,1H),8.23(dd,J=10.0,1.5 Hz,1H),8.01-7.95(m,1H),7.84(td,J=10.0,1.0 Hz,1H),7.77-7.74(m,2H),7.71-7.67(m,3H),4.19(s,3H).

[0341] 13 C NMR(126 MHz,DMSO-d6)δ172.91,144.41,138.47,135.61,135.26,133.99,131.95, 131.41,131.18,131.04,129.83,127.44,126.91,126.62,125.20,39.40.

[0342] HRMS (ESI-TOF): m / z theoretical value: C 18 H 14 N3O2[MI] + 304.1081, Actual value: 304.1085.

[0343] compound 105 [ka] (E)-4-(Hydroxyimino)-1-homotrimethyl-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1H NMR(500 MHz,DMSO-d6)δ14.58(s,1H),9.81(s,1H),9.29(dd,J=10.0,0.5 Hz,1H),8.18(dd,J=10.0,1.0 Hz,1H),8.03-7.93(m,1H),7.82(td,J=10.0,1.0 Hz,1H),7.16(s,2H),4.20(s,3H),2.38(s,3H),2.04(s,6H).

[0344] 13 C NMR(126 MHz,DMSO-d6)δ173.08,144.26,140.75,138.74,136.36,135.27,135.12,131.82 ,131.44,130.87,130.41,129.56,127.35,127.27,124.97,39.78,21.15,17.54.

[0345] HRMS (ESI-TOF): m / z theoretical value: C 21 H 20 N3O2[MI] + 346.1550, Actual value: 346.1555.

[0346] compound 106 [ka] (E)-4-(Hydroxyimino)-3-methyl-9-oxo-1-(thiophen-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ13.01(s,1H),8.49(s,1H),8.27(d,J=7.8 Hz,1H),8.12(dd,J=8.0,1.6 Hz,1H),7.69(t,J=7.6 Hz,1H),7.60(t,J=7.1 Hz,1H),7.43(d,J=5.9 Hz,1H),7.19(d,J=3.0 Hz,1H),6.95(dd,J=5.1,3.5 Hz,1H),5.88(s,2H),4.28(s,3H).

[0347] HRMS (ESI-TOF): m / z theoretical value: C 17 H 14 N3O2[MI] + 324.0801, Actual value: 324.0802.

[0348] Compound 107 [ka] (E)-1-((1,3-dioxan-2-yl)methyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.53(s,1H),9.64(s,1H),9.25(dd,J=10.0,0.5 Hz,1H),8.33(dd,J=10.0,1.5 Hz,1H),8.01-7.93(m,1H),7.85(td,J=10.0,1.0 Hz,1H),5.34(t,J=3.5 Hz,1H),4.91(d,J=5.0 Hz,2H),4.16(s,3H),3.86(s,4H).

[0349] 13 C NMR(126 MHz,DMSO-d6)δ174.18,144.11,138.36,135.52,135.39,131.89,131.45,130.83,127.43,127.06,125.01,99.99,65.37,49.50,39.28.

[0350] HRMS (ESI-TOF): m / z theoretical value: C 16 H 15 N3O4[MI] + 314.1135, Actual value: 314.1136.

[0351] compound 108 [ka] (E)-1-(4-Fluorobenzyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.54(s,1H),9.71(s,1H),9.24(dd,J=10.0,0.5 Hz,1H),8.31(dd,J=10.0,1.5 Hz,1H),7.96(td,J=10.0,1.5 Hz,1H),7.83(td,J=10.0,1.0 Hz,1H),7.57(dd,J=10.0,5.0 Hz,2H),7.28(t,J=10.0 Hz,2H),5.85(s,2H),4.12(s,3H).

[0352] 13 C NMR(126 MHz,DMSO-d6)δ174.02,163.66(161.71,J=243.8 Hz),143.70,138.45,136.13,135.39,131.89,131.45,131.20(131.14,J=7.5 Hz),130.89(130.87,J=2.5 Hz),130.76,127.40,127.12,124.57,116.29(116.12,J=21.3 Hz),51.15,39.33.

[0353] HRMS (ESI-TOF): m / z theoretical value: C 19 H 15 FN3O2[MI] + 336.1143, Actual value: 336.1138.

[0354] Compound 109 [ka] (E)-1-(2-Fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1H NMR(500 MHz,DMSO-d6)δ14.68(s,1H),10.08(s,1H),9.29(dd,J=10.0,1.0 Hz,1H),8.24(dd,J=10.0,1.5 Hz,1H),8.03-7.95(m,1H),7.89-7.77(m,3H),7.68-7.61(m,1H),7.54(td,J=10.0,1.0 Hz,1H),4.21(s,3H).

[0355] 13 C NMR(126 MHz,DMSO)δ172.95,157.58(155.57,J=251.3 Hz),145.03,138.34,135.74,135.52,133.83(133.77,J=7.5 Hz),132.01,131.52,130.65,128.91,127.34,127.06,125.88(125.85,J=3.8 Hz),125.17,121.97(121.87,J=12.5 Hz),117.28(117.13,J=18.8 Hz),39.62.

[0356] HRMS (ESI-TOF): m / z theoretical value: C 18 H 13 FN3O2[MI] + 322.0986, Actual value: 322.0986.

[0357] compound 110 [ka] (E)-1-(3-Fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1H NMR (400 MHz, DMSO-d6) δ14.64(s,1H),10.04(d,J=0.4 Hz,1H),9.28(dd,J=8.0,0.8 Hz,1H),8.25(dd,J=8.0,1.2 Hz,1H),8.03-7.95(m,1H),7.85(td,J=8.0,1.2 Hz,1H),7.80-7.71(m,2H),7.66-7.54(m,2H),4.20(s,3H).

[0358] 13 C NMR (101 MHz, DMSO) δ172.90,163.16(160.72,J=244.0 Hz),144.62,138.38,135.43,135.33,135.07(134.96,J=11.0 Hz),131.98,131.76(131.67,J=9.0 Hz),131.41,130.99,127.49,126.87,125.21,123.05(123.02,J=3.0 Hz),118.47(118.26,J=21.0 Hz),114.78(114.53,J=25.0 Hz),39.45.

[0359] HRMS(ESI-TOF):m / zTheoretical value:C 18 H 13 FN3O2[MI] + 322.0986, measured value: 322.0982.

[0360] Compound 111

change

[0361] 13 C NMR(126 MHz,DMSO)δ172.97,164.38(162.40,J=1910.0 Hz),144.56,138.40,135.41(135.31,J=10.0 Hz),131.97,131.44,130.99,130.26,130.24,129.22(129.14,J=10.0 Hz),127.44,126.91,125.32,116.93(116.74,J=19.0 Hz),39.39.

[0362] HRMS (ESI-TOF): m / z theoretical value: C 18 H 13 FN3O2[MI] + 322.0986, Actual value: 322.0991.

[0363] compound 112 [ka] (E)-1-(2-Fluorobenzyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.55(s,1H),9.71(s,1H),9.25(dd,J=10.0,1.0 Hz,1H),8.29(dd,J=10.0,1.5 Hz,1H),7.96(td,J=10.0,1.5 Hz,1H),7.83(td,J=10.0,1.0 Hz,1H),7.52-7.43(m,2H),7.37-7.30(m,1H),7.24(td,J=10.0,1.0 Hz,1H),5.94(s,2H),4.14(s,3H).

[0364] 13C NMR(126 MHz,DMSO-d6)δ173.93,161.62(159.66,J=245.0 Hz),144.04,138.44,136.14,135.42,131.90,131.61(131.55,J=7.5 Hz),131.46,130.70,130.67,127.40,127.13,125.35(125.32,J=3.8 Hz),124.67,121.80(121.69,J=13.8 Hz),116.23(116.07,J=20.0 Hz),46.44(46.41,J=3.8 Hz),39.32.

[0365] HRMS (ESI-TOF): m / z theoretical value: C 19 H 15 FN3O2[MI] + 336.1143, Actual value: 336.1145.

[0366] compound 113 [ka] (E)-1-(3-Fluorobenzyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.55(s,1H),9.74(s,1H),9.25(dd,J=10.0,1.0 Hz,1H),8.30(dd,J=10.0,2.0 Hz,1H),7.96(td,J=10.0,1.5 Hz,1H),7.83(td,J=10.0,1.0 Hz,1H),7.50-7.45(m,1H),7.36-7.29(m,2H),7.26-7.18(m,1H),5.89(s,2H),4.13(s,3H).

[0367] 13C NMR(126 MHz,DMSO-d6)δ173.96,163.70(161.76,J=242.5 Hz),143.95,138.48,137.47(137.41,J=7.5 Hz),136.15,135.39,131.88,131.45,131.39(131.32,J=8.8 Hz),130.75,127.40,127.15,124.61,124.59,115.98(115.82,J=20.0 Hz),115.41(115.23,J=22.5 Hz),51.21,39.38.

[0368] HRMS (ESI-TOF): m / z theoretical value: C 19 H 15 FN3O2[MI] + 336.1143, Actual value: 336.1146.

[0369] compound 114 [ka] (E)-4-(Hydroxyimino)-1-(4-methoxyphenyl)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.58(s,1H),9.92(s,1H),9.27(dd,J=10.0,1.0 Hz,1H),8.24(dd,J=10.0,1.5 Hz,1H),8.01-7.93(m,1H),7.84(td,J=10.0,1.5 Hz,1H),7.66(d,J=10.0 Hz,2H),7.21(d,J=10.0 Hz,2H),4.17(s,3H),3.89(s,3H).

[0370] 13 C NMR(126 MHz,DMSO-d6)δ172.93,161.12,144.32,138.47,135.44,135.22,131.94,131 .40,131.08,127.96,127.42,126.91,126.64,125.31,114.85,56.23,39.30.

[0371] HRMS (ESI-TOF): m / z theoretical value: C 19 H 16 N3O3[MI] + 334.1186, Actual value: 334.1184.

[0372] compound 115 [ka] (E)-4-(Hydroxyimino)-1-(4-methoxybenzyl)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.51(s,1H),9.68(s,1H),9.23(dd,J=10.0,1.0 Hz,1H),8.32(dd,J=10.0,1.0 Hz,1H),7.99-7.91(m,1H),7.83(td,J=10.0,1.0 Hz,1H),7.52-7.45(m,2H),7.04-6.96(m,2H),5.79(s,2H),4.10(s,3H),3.76(s,3H).

[0373] 13 C NMR(126 MHz,DMSO-d6)δ174.06,160.08,143.40,138.44,136.09,135.36,131.88,131.43 ,130.78,130.66,127.41,127.09,126.36,124.56,114.74,55.72,51.49,39.29.

[0374] HRMS (ESI-TOF): m / z theoretical value: C 20 H 18 N3O3[MI] + 348.1343, Actual value: 348.1347.

[0375] compound 116 [ka] (E)-1-(3-chloro-4-fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ14.66(s,1H),10.02(s,1H),9.28(dd,J=10.0,1.0 Hz,1H),8.26(dd,J=10.0,1.5 Hz,1H),8.17(dd,J=10.0,2.5 Hz, 1H), 7.99 (td, J=5.0, 1.5 Hz, 1H), 7.88-7.77 (m, 3H), 4.20 (s, 3H).

[0376] 13 C NMR(126 MHz,DMSO-d6)δ173.01,159.77(157.78,J=250.0 Hz),144.77,138.33,135.39,135.23,132.01,131.44,130.92,130.75(130.72,J=3.8 Hz),129.46,128.10(1210.03,J=8.8 Hz),127.49,126.88,125.30,120.56(120.40,J=20.0 Hz),118.20(118.02,J=22.5 Hz),39.46.

[0377] HRMS (ESI-TOF): m / z theoretical value: C 18 H 12 ClFN3O2[MI] + 356.0597, Actual value: 356.0593.

[0378] compound 117 [ka] (E)-1-(3-Bromo-4-fluorophenyl)-4-(hydroxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 11H NMR (400 MHz, DMSO-d6) δ 14.65 (s, 1H), 10.02 (s, 1H), 9.28 (dd, J = 8.0, 1.2 Hz, 1H), 8.33 - 8.20 (m, 2H), 8.02 - 7.95 (m, 1H), 7.90 - 7.80 (m, 2H), 7.75 (t, J = 8.0 Hz, 1H), 4.19 (s, 3H).

[0379] 13 13C NMR (101 MHz, DMSO) δ 173.01, 161.09 (158.62, J = 247.0 Hz), 144.79, 138.33, 135.38, 135.20, 132.12 (131.99, J = 13.0 Hz), 131.44, 130.97, 130.93, 130.92, 128.70 (128.61, J = 9.0 Hz), 127.48, 126.88, 125.32, 117.93 (117.69, J = 24.0 Hz), 108.84 (108.62, J = 22.0 Hz), 39.44.

[0380] HRMS (ESI-TOF): m / z calculated value: C 18 H 12 BrFN3O2 [M - I] + 400.0091, found value: 400.0088.

[0381] Compound 118

Chemical Structure

[0382] HRMS (ESI-TOF): m / z calculated value: C 18 H 12 BrFN3O2 [M - I]+ 287.0775, Actual value: 287.0778.

[0383] Example 12 Compound 1 (0.05 mmol) was added to 3 mL of acetonitrile and 310 μL of methyl iodide, and reacted for 48 hours at 70° C. After the reaction was completed, the solvent was removed to obtain a yellow solid, which was slurried for half an hour and then suction filtered to obtain the final product.

[0384] Using the above different synthetic intermediate compounds, compounds 119 to 126 can be prepared by the method of Example 12, and the materials and reaction conditions of other compounds are unchanged, and the raw materials are all commercially available.

[0385] Compound 119 [ka] (E) and (Z)-1-Butyl-4-(methoxyimino)-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ9.65(s,1H),9.02(dd,J=5.0,0.5 Hz,1H),8.35(dd,J=10.0,1.0 Hz,1H),7.99-7.92(m,1H),7.88(td,J=5.0,1.0 Hz,1H),4.60(t,J=7.0 Hz,2H),4.41(s,3H),4.13(s,3H),1.93-1.81(m,2H),1.43-1.35(m,2H),0.95(t,J=5.0 Hz,3H).

[0386] 13 C NMR(126 MHz,DMSO-d6)δ173.98,143.58,138.41,135.35,134.86,132.54,131.66,1 31.22,127.73,126.70,125.33,66.37,49.06,39.25,31.67,19.28,13.86.

[0387] HRMS(ESI-TOF):m / zTheoretical value:C 17 H 20 N3O2[MI] + 298.1550, measured value: 298.1555.

[0388] Compound 120

change

[0389] 1 H NMR(500 MHz, DMSO-d6)δ9.67(s,1H),9.05(d,J=10.0 Hz,1H),8.34(dd,J=10.0,1.5 Hz,1H),7.98(td,J=10.0 1.5 Hz,1H),7.88(td,J=10.0,1.0 Hz,1H),4.67(q,J=7.0 Hz,2H),4.60(t,J=7.0 Hz,2H),4.13(s,3H),1.94-1.82(m,2H),1.50(t,J=7.0 Hz,3H),1.42-1.33(m,2H),0.95(t,J=7.5 Hz,3H).

[0390] 13 C NMR(126 MHz, DMSO-d6)δ173.97,143.54,138.27,135.36,135.06,132.45,131.55,131. 19,127.70,126.73,125.24,74.48,49.06,39.33,31.67,19.28,15.04,13.87.

[0391] HRMS(ESI-TOF):m / zTheoretical value:C 18 H 22 N3O2[MI] + 312.1707, measured value: 312.1707.

[0392] Compound 121 [ka] (E) and (Z)-4-((benzyloxy)imino)-1-butyl-3-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 122-124°C.

[0393] 1 H NMR(500 MHz,DMSO-d6)δ9.62(s,1H),9.09(d,J=10.0 Hz,1H),8.34(dd,J=10.0,1.0 Hz,1H),8.01-7.94(m,1H),7.88(td,J=10.0,1.0 Hz,1H),7.61-7.54(m,2H),7.48-7.37(m,3H),5.68(s,2H),4.57(t,J=7.0 Hz,2H),4.03(s,3H),1.90-1.77(m,2H),1.41-1.32(m,2H),0.97-0.90(m,3H).

[0394] 13 C NMR(126 MHz,DMSO)δ173.94,143.58,138.73,136.71,135.39,134.89,132.57,131.60,131.25,12 9.47,129.21,129.18,127.76,126.70,125.35,80.08,49.03,39.33,31.66,19.24,13.85.

[0395] HRMS (ESI-TOF): m / z theoretical value: C 23 H 23 N3O2[MI] + 374.1863, Actual value: 374.1863.

[0396] compound 122 [ka] (E) and (Z)-1-Butyl-3-ethyl-4-(methoxyimino)-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 135~137℃.

[0397] 1 H NMR(500 MHz, DMSO-d6)δ9.71(s,1H),9.02(d,J=10.0 Hz,1H),8.34(d,J=10.0,1H),7.97(td,J=10.0,1.5 Hz,1H),7.88(t,J=10.0,1H),4.65-4.55(m,5H),4.41(s,3H),1.92-1.83(m,3H),1.54(t,J=7.0 Hz,3H),1.47-1.35(m,3H),0.95(t,J=7.0 Hz,4H).

[0398] 13 C NMR(126 MHz, DMSO-d6)δ174.09,142.86,138.14,135.34,134.19,132.51,131.70,131. 11,127.70,126.81,125.71,66.27,49.20,47.07,31.65,19.35,14.86,13.89.

[0399] HRMS(ESI-TOF):m / zTheoretical value:C 18 H 22 N3O2[MI] + 312.1707, measured value: 312.1708.

[0400] Compound 123

change

[0401] 11H NMR (400 MHz, DMSO-d6) δ 9.58 (s, 1H), 9.01 (d, J = 8.0, 1H), 8.33 (dd, J = 4.0, 1.2 Hz, 1H), 7.97 (td, J = 8.0, 1.6 Hz, 1H), 7.88 (td, J = 8.0, 1.2 Hz, 1H), 4.41 (s, 3H), 4.18 (s, 3H), 4.13 (s, 3H).

[0402] 13 13C NMR (101 MHz, DMSO) δ 174.16, 144.05, 138.25, 135.38, 134.26, 132.56, 131.72, 131.10, 127.63, 126.76, 125.85, 66.37, 39.08, 36.44.

[0403] HRMS (ESI-TOF): m / z calculated value: C 14 H 14 N3O2 [M-I] + 256.1081, measured value: 256.1085.

[0404] Compound 124

Chemical Structure

[0405] 1 1H NMR (500 MHz, DMSO-d6) δ 9.57 (s, 1H), 9.06 (dd, J = 10.0, 1.0 Hz, 1H), 8.34 (dd, J = 10.0, 1.0 Hz, 1H), 7.98 (td, J = 10.0, 1.5 Hz, 1H), 7.88 (td, J = 5.0, 1.0 Hz, 1H), 4.67 (q, J = 7.0 Hz, 2H), 4.18 (s, 3H), 4.13 (s, 3H), 1.50 (t, J = 7.0 Hz, 3H).

[0406] 13C NMR(126 MHz,DMSO-d6)δ174.18,144.02,138.15,135.39,134.49,132.49,131.62,131.11,127.63,126.81,125.80,74.48,39.12,36.43,15.02.

[0407] HRMS (ESI-TOF): m / z theoretical value: C 15 H 15 N3O2[MI] + 270.1243, Actual value: 270.1244.

[0408] compound 125 [ka] (E)-4-((benzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 177-179°C.

[0409] 1 H NMR(500 MHz,DMSO-d6)δ9.53(s,1H),9.08(dd,J=10.0,1.0 Hz,1H),8.33(dd,J=10.0,1.0 Hz,1H),8.01-7.93(m,1H),7.88(td,J=10.0,1.0 Hz,1H),7.60-7.55(m,2H),7.49-7.38(m,3H),5.68(s,2H),4.16(s,3H),4.03(s,3H).

[0410] 13 C NMR(126 MHz,DMSO-d6)δ174.15,144.04,138.61,136.66,135.42,134.32,132.61,131.66 ,131.16,129.49,129.23,129.19,127.67,126.77,125.90,80.09,39.13,36.39.

[0411] (Z)-4-((benzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.57 (s,1H),8.22 (d,J=8.1 Hz,1H),8.15(d,J=7.8 Hz,1H),7.86(t,J=7.7 Hz,1H),7.75(t,J=7.6 Hz,1H),7.54(d,J=7.1 Hz, 2H), 7.41 (d, J=8.2 Hz, 3H), 5.57 (s, 2H), 4.13 (s, 3H), 4.00 (s, 3H).

[0412] (E) and (Z)-4-((benzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.55(s,3H),9.50(s,1H),9.04(d,J=8.0 Hz,1H),8.29(dd,J=8.0,1.6 Hz,1H),8.20(dd,J=8.0,1.2 Hz,3H),8.13(dd,J=7.8,1.4 Hz,3H),7.97-7.90(m,1H),7.84(td,J=7.6,1.6 Hz,4H),7.73(td,J=7.6,1.2 Hz,3H),7.59-7.48(m,8H),7.47-7.33(m,12H),5.64(s,2H),5.55(s,6H),4.11(s,3H),4.11(s,6H),3.99(s,3H),3.98(s,6H).

[0413] HRMS (ESI-TOF): m / z theoretical value: C 20 H 18 N3O2[MI] + 332.1394, Actual value: 332.1402.

[0414] compound 126 [ka] (E) and (Z)-3-Ethyl-4-(methoxyimino)-1-methyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 162-164°C.

[0415] 1 H NMR(500 MHz,DMSO-d6)δ9.57(s,1H),9.06(d,J=10.0 Hz,1H),8.34(dd,J=10.0,2.0 Hz,1H),7.98(td,J=10.0,2.0 Hz,1H),7.88(td,J=10.0,1.5 Hz,1H),4.67(q,J=7.0 Hz,2H),4.18(s,3H),4.13(s,3H),1.50(t,J=7.0 Hz,3H).

[0416] 13 C NMR(126 MHz,DMSO-d6)δ174.18,144.02,138.15,135.39,134.49,132.49,131.62,131.11,127.63,126.81,125.80,74.48,39.12,36.43,15.02.

[0417] HRMS (ESI-TOF): m / z theoretical value: C 15 H 16 N3O2[MI] + 270.1237, Actual value: 270.1241.

[0418] Example 13 Compound 1 (0.05 mmol) was added to 3 mL of acetonitrile and 150 μL of methyl iodide, and reacted for 8 hours at 100° C. After the reaction was completed, the solvent was removed to obtain a yellow solid, which was slurried for half an hour and then suction filtered to obtain the final product.

[0419] Using the above different synthetic intermediate compounds, compounds 127 to 151 can be prepared by the method of Example 13, and the materials and reaction conditions of other compounds are unchanged, and the raw materials are all commercially available.

[0420] compound 127 [ka] (E) and (Z)-4-(isopropoxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 187-189°C.

[0421] 1 H NMR(400 MHz,DMSO-d6)δ9.58(s,1H),9.07(dd,J=8.0,0.4 Hz,1H),8.34(dd,J=8.0,1.2 Hz,1H),8.03-7.95(m,1H),7.88(td,J=8.0,1.2 Hz,1H),4.92-4.82(m,1H),4.18(s,3H),4.14(s,3H),1.51(d,J=8.0 Hz,6H).

[0422] 13 C NMR(101 MHz,DMSO-d6)δ174.16,143.98,137.79,135.40,134.67,132.39,131.52,131.09,127.60,126.84,125.73,81.42,39.23,36.45,21.77.

[0423] HRMS (ESI-TOF): m / z theoretical value: C 16 H 18 N3O2[MI] + 284.1394, Actual value: 284.1399.

[0424] compound 128 [ka] (E) and (Z)-4-(Butoxyimine)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 201-203°C.

[0425] 11H NMR (500 MHz, DMSO-d6) δ 9.59 (s, 1H), 9.03 (dd, J = 8.0, 1.0 Hz, 1H), 8.34 (dd, J = 8.0, 1.5 Hz, 1H), 8.02 - 7.93 (m, 1H), 7.90 - 7.85 (m, 1H), 4.64 (t, J = 6.5 Hz, 2H), 4.18 (s, 3H), 4.12 (s, 3H), 1.95 - 1.77 (m, 2H), 1.53 - 1.42 (m, 2H), 0.98 (t, J = 7.5 Hz, 3H).

[0426] 13 13C NMR (126 MHz, DMSO-d6) δ 174.16, 144.02, 138.15, 135.43, 134.46, 132.49, 131.48, 131.10, 127.64, 126.80, 125.78, 78.53, 39.11, 36.43, 31.07, 19.09, 14.20.

[0427] HRMS (ESI-TOF): m / z theoretical value: C 17 H 20 N3O2[M-I] + 298.1550, found: 298.1551.

[0428] Compound 129

Chem.

[0429] 1 1H NMR (500 MHz, DMSO-d6) δ 9.57 (s, 1H), 9.03 (J = 10.0 Hz, 1H), 8.35 (dd, J = 10.0, 1.5 Hz, 1H), 8.05 - 7.98 (m, 1H), 7.89 (t, J = 7.5 Hz, 1H), 4.44 (d, J = 6.5 Hz, 2H), 4.18 (s, 3H), 4.12 (s, 3H), 2.30 - 2.15 (m, 1H), 1.05 (d, J = 5.0 Hz, 6H).

[0430] 13 C NMR(126 MHz,DMSO-d6)δ174.16,144.03,138.16,135.45,134.47,132.51,131.41,131.13,127.69,126.82,125.81,84.91,39.11,36.43,28.32,19.37.

[0431] HRMS (ESI-TOF): m / z theoretical value: C 17 H 20 N3O2[MI] + 298.1550, Actual value: 298.1551.

[0432] compound 130 [ka] (E) and (Z)-4-(tert-butoxyimino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 221-223°C.

[0433] 1 H NMR(500 MHz,DMSO-d6)δ9.59(s,1H),9.10(dd,J=10.0 Hz,1H),8.35(dd,J=5.0,1.5 Hz, 1H), 8.02-7.95 (m, 1H), 7.91-7.85 (m, 1H), 4.19 (s, 3H), 4.15 (s, 3H), 1.56 (s, 9H).

[0434] 13 C NMR(126 MHz,DMSO-d6)δ174.19,143.95,137.64,135.39,134.97,132.32,131.49,131.12,127.59,126.94,125.70,85.60,39.44,36.44,27.70,27.65.

[0435] HRMS (ESI-TOF): m / z theoretical value: C 17 H 20N3O2[MI] + 298.1550, Actual value: 298.1551.

[0436] Compound 131 [ka] (E) and (Z)-4-((cyclopropylmethoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 170-172°C.

[0437] 1 H NMR(400 MHz,DMSO-d6)δ9.58(s,1H),9.09(dd,J=8.0,0.4 Hz,1H),8.34(dd,J=8.0,1.6 Hz,1H),8.03-7.95(m,1H),7.88(td,J=8.0,1.2 Hz,1H),4.47(d,J=8.0 Hz,2H),4.18(s,4H),4.13(s,3H),1.47-1.35(m,1H),0.70-0.62(m,2H),0.51-0.42(m,2H).

[0438] 13 C NMR(101 MHz,DMSO-d6)δ174.17,144.01,1310.08,135.38,134.48,132.46,131.56,131.11,127.62,126.88,125.79,83.19,39.14,36.44,10.70,3.76.

[0439] HRMS (ESI-TOF): m / z theoretical value: C 17 H 18 N3O2[MI] + 296.1394, Actual value: 296.1397.

[0440] compound 132 [ka] (E) and (Z)-4-((allyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 139-141°C.

[0441] 1 H NMR(400 MHz,DMSO-d6)δ9.57(s,1H),9.04(dd,J=8.0,1.2 Hz,1H),8.34(dd,J=8.0,1.2 Hz,1H),7.99(td,J=8.0,1.2 Hz,1H),7.89(td,J=8.0,1.2 Hz,1H),6.28-6.15(m,1H),5.58-5.50(m,1H),5.46-5.39(m,1H),5.12(d,J=8.0 Hz,2H),4.18(s,3H),4.10(s,3H).

[0442] 13 C NMR(101 MHz,DMSO-d6)δ174.16,144.07,138.48,135.41,134.38,133.51,132.59 ,131.66,131.13,127.67,126.74,125.88,120.67,79.10,39.17,36.44.

[0443] HRMS (ESI-TOF): m / z theoretical value: C 16 H 16 N3O2[MI] + 282.1237, Actual value: 282.1239.

[0444] compound 133 [ka] (E) and (Z)-4-(((4-methoxybenzyl)oxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1H NMR(400 MHz,DMSO-d6)δ9.54(s,1H),9.05(dd,J=10.0,0.8 Hz,1H),8.32(dd,J=8.0,1.2 Hz,1H),8.02-7.92(m,1H),7.86(td,J=8.0,1.2 Hz,1H),7.56-7.49(m,2H),7.03-6.95(m,2H),5.60(s,2H),4..16(s,3H),4.06(s,3H),3.77(s,3H).

[0445] 13 C NMR(101 MHz,DMSO-d6)δ174.13,160.14,144.02,138.38,135.38,134.37,132.53,131.58,13 1.44,131.11,128.50,127.63,126.79,125.83,114.51,79.91,55.65,39.22,36.41.

[0446] HRMS (ESI-TOF): m / z theoretical value: C 21 H 20 N3O3[MI] + 363.11499, Actual value: 363.1499.

[0447] compound 134 [ka] (E) and (Z)-4-(((4-chlorobenzyl)oxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.54(s,1H),9.07(dd,J=8.0,0.8 Hz,1H),8.33(dd,J=8.0,1.6 Hz,1H),8.01-.95(m,1H),7.88(td,J=8.0,1.2 Hz,1H),7.65-7.58(m,2H),7.55-7.48(m,2H),5.67(s,2H),4.16(s,3H),4.02(s,3H).

[0448] 13C NMR(101 MHz,DMSO-d6)δ174.14,144.05,138.81,135.74,135.43,134.25,133.88,132.66 ,131.75,131.41,131.16,129.19,127.68,126.73,125.93,78.99,39.17,36.41.

[0449] HRMS (ESI-TOF): m / z theoretical value: C 20 H 17 ClN3O2[MI] + 366.1004, Actual value: 366.1006.

[0450] compound 135 [ka] (E) and (Z)-1,3-Dimethyl-9-oxo-4-(((4-(trifluoromethyl)benzyl)oxy)imino))-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 158-160°C.

[0451] 1 H NMR(400 MHz,DMSO-d6)δ9.53(s,1H),9.11(dd,J=8.0,0.8 Hz,1H),8.34(dd,J=8.0,0.8 Hz,1H),7.99(td,J=8.0,1.6 Hz,1H),7.89(td,J=8.0,1.2 Hz, 1H), 7.86-7.76 (m, 4H), 5.78 (s, 2H), 4.16 (s, 3H), 4.00 (s, 3H).

[0452] 13 C NMR(101 MHz,DMSO-d6)δ174.14,144.07,141.53,139.03,135.46,134.20,132.73,131.84 ,131.19,129.63,129.32,127.71,126.72,126.11(126.08,126.04,126.00,J=4.0 Hz),123.26,78.84,39.12,36.41.

[0453] HRMS (ESI-TOF): m / z theoretical value: C 21 H 17 F3N3O2[MI] + 400.1267, Actual value: 400.1268.

[0454] compound 136 [ka] (E) and (Z)-4-(((4-fluorobenzyl)oxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide Yellow solid, melting point: 175-177°C.

[0455] 1 H NMR(400 MHz,DMSO-d6)δ9.54(s,1H),9.07(d,J=8.0 Hz,1H),8.32(dd,J=8.0,1.2 Hz,1H),7.97(td,J=8.0,1.6 Hz,1H),7.88(td,J=8.0,1.2 Hz,1H),7.69-7.56(m,2H),7.35-7.24(m,2H),5.66(s,2H),4.16(s,3H),4.03(s,3H).

[0456] 13 C NMR(101 MHz,DMSO-d6)δ174.14,163.99(161.55,J=244.0 Hz),144.04,138.68,135.40,134.29,133.02(132.99,J=3.0 Hz),132.62,131.98(131.89,J=9.0 Hz),131.70,131.15,127.66,126.75,125.91,116.14(115.93,J=21.0 Hz),79.14,39.18,36.41.

[0457] HRMS (ESI-TOF): m / z theoretical value: C 20 H 17 FN3O2[MI] + 350.1299, Actual value: 350.1302.

[0458] compound 137 [ka] (E) and (Z)-1,3-Dimethyl-9-oxo-4-(((perfluorophenyl)methoxy)imino)-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.54(s,1H),8.94(d,J=8.0 Hz,1H),8.30(d,J=8.0 Hz,1H),8.02-7.92(m,1H),7.87(t,J=8.0 Hz, 1H), 5.78 (s, 2H), 4.14 (s, 3H), 4.03 (s, 3H).

[0459] 13 C NMR(126 MHz,DMSO-d6)δ175.44,174.10,144.09,139.74,135.84,135.44,133.92,132.92 ,132.27,131.84,131.26,127.79,127.39,126.66,126.23,66.49,38.71,36.47.

[0460] HRMS (ESI-TOF): m / z theoretical value: C 20 H 13 F5N3O2[MI] + 422.0922, Actual value: 422.0920.

[0461] compound 138 [ka] (E) and (Z) 4-((benzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-bromide 1H NMR(500 MHz,DMSO-d6)δ9.53(s,1H),9.08(dd,J=10.0,1.0 Hz,1H),8.33(dd,J=10.0,1.0 Hz,1H),8.01-7.93(m,1H),7.88(td,J=10.0,1.0 Hz,1H),7.60-7.55(m,2H),7.49-7.38(m,3H),5.68(s,2H),4.16(s,3H),4.03(s,3H).

[0462] 13 C NMR(126 MHz,DMSO-d6)δ174.15,144.04,138.61,136.66,135.42,134.32,132.61,131.66 ,131.16,129.49,129.23,129.19,127.67,126.77,125.90,80.09,39.13,36.39.

[0463] HRMS (ESI-TOF): m / z theoretical value: C 20 H 18 N3O2[MI] + 322.1394, Actual value: 322.1393.

[0464] compound 139 [ka] (E) and (Z)-4-((benzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-p-toluenesulfonate 1 H NMR(500 MHz,DMSO-d6)δ9.53(s,1H),9.08(dd,J=10.0,1.0 Hz,1H),8.33(dd,J=10.0,1.0 Hz,1H),8.01-7.93(m,1H),7.88(td,J=10.0,1.0 Hz,1H),7.60-7.55(m,2H),7.49-7.38(m,3H),5.68(s,2H),4.16(s,3H),4.03(s,3H).

[0465] 13C NMR(126 MHz,DMSO-d6)δ174.15,144.04,138.61,136.66,135.42,134.32,132.61,131.66 ,131.16,129.49,129.23,129.19,127.67,126.77,125.90,80.09,39.13,36.39.

[0466] HRMS (ESI-TOF): m / z theoretical value: C 20 H 18 N3O2[MI] + 322.1394, Actual value: 322.1393.

[0467] compound 140 [ka] (E) and (Z)-4-((benzyloxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-sulfate dimethyl ester 1 H NMR(500 MHz,DMSO-d6)δ9.53(s,1H),9.08(dd,J=10.0,1.0 Hz,1H),8.33(dd,J=10.0,1.0 Hz,1H),8.01-7.93(m,1H),7.88(td,J=10.0,1.0 Hz,1H),7.60-7.55(m,2H),7.49-7.38(m,3H),5.68(s,2H),4.16(s,3H),4.03(s,3H).

[0468] 13 C NMR(126 MHz,DMSO-d6)δ174.15,144.04,138.61,136.66,135.42,134.32,132.61,131.66 ,131.16,129.49,129.23,129.19,127.67,126.77,125.90,80.09,39.13,36.39.

[0469] HRMS (ESI-TOF): m / z theoretical value: C 20 H 18 N3O2[MI] +322.1394, Actual value: 322.1395.

[0470] compound 141 [ka] (E) and (Z)-1,3-Dimethyl-4-(((4-nitrobenzyl)oxy)imino)-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(500 MHz,DMSO-d6)δ9.54(s,1H),9.11(d,J=10.0 Hz,1H),8.35-8.28(m,3H),8.00(td,J=10.0,1.5 Hz,1H),7.90(td,J=10.0,1.0 Hz, 1H), 7.84 (d, J=10.0 Hz, 2H), 5.83 (s, 2H), 4.16 (s, 3H), 3.98 (s, 3H).

[0471] 13 C NMR(126 MHz,DMSO-d6)δ174.14,147.97,144.44,144.09,139.22,135.47,134.14,132.79 ,131.92,131.21,130.21,127.74,126.70,126.04,124.28,78.38,39.14,36.44.

[0472] HRMS (ESI-TOF): m / z theoretical value: C 20 H 17 N4O4[MI] + 377.1244, Actual value: 377.1247.

[0473] compound 142 [ka] (E) and (Z)-4-((phenoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 11H NMR (400 MHz, DMSO-d6) δ 9.62 (s, 3H), 9.56 (s, 1H), 9.07 (d, J = 8.0 Hz, 1H), 8.35 (dd, J = 8.0, 1.6 Hz, 1H), 8.29 (dd, J = 8.0, 1.2 Hz, 3H), 8.18 (dd, J = 7.8, 1.4 Hz, 3H), 8.03 - 7.95 (m, 1H), 7.89 (td, J = 7.6, 1.6 Hz, 4H), 7.79 (td, J = 7.6, 1.2 Hz, 3H), 7.69 - 7.58 (m, 8H), 7.49 - 7.36 (m, 12H), 4.14 (s, 3H), 4.13 (s, 6H), 4.02 (s, 3H), 4.00 (s, 6H).

[0474] HRMS (ESI-TOF): m / z theoretical value: C 20 H 18 N3O2[M-I] + 318.1237, found: 318.1238.

[0475] Compound 143

Chemical Structure

[0476] HRMS (ESI-TOF): m / z theoretical value: C 20 H 18 N3O2[M-I] + 328.1292, found: 328.1297.

[0477] compound 144 [ka] (E)-4-((2-Methoxyethoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.55(s,1H),9.02(d,J=8.0 Hz,1H),8.32(d,J=8.0 Hz,1H),7.96(t,J=8.0 Hz,1H),7.86(t,J=8.0 Hz,1H),4.73(t,J=4.0 Hz,2H),4.16(s,3H),4.11(s,3H),3.81(t,J=4.0 Hz,2H),3.32(s,3H).

[0478] 13 C NMR(126 MHz,DMSO-d6)δ174.17,144.02,138.40,135.39,134.38,132.57,131.62,131.14,127.65,126.78,125.88,77.73,70.56,58.77,39.12,36.45.

[0479] HRMS (ESI-TOF): m / z theoretical value: C 16 H 18 N3O3[MI] + 300.1343, Actual value: 300.1347.

[0480] compound 145 [ka] (E)-4-((2-(benzyloxy)ethoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 11H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 9.04 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 8.0 Hz, 1H), 7.94 (t, J = 8.0 Hz, 1H), 7.87 (t, J = 8.0 Hz, 1H), 7.34 - 7.19 (m, 4H), 4.76 (t, J = 4.0 Hz, 2H), 4.56 (s, 2H), 4.16 (s, 3H), 4.03 (s, 3H), 3.90 (t, J = 4.0 Hz, 2H).

[0481] 13 13C NMR (126 MHz, DMSO-d6) δ 174.17, 144.00, 138.69, 138.43, 135.32, 134.33, 132.59, 131.65, 131.15, 128.71, 1210.04, 127.98, 127.65, 126.79, 125.87, 77.75, 72.48, 68.19, 39.03, 36.46.

[0482] HRMS (ESI-TOF): m / z calculated value: C 22 H 22 N3O3[M-I] + 376.1656, found value: 376.1656.

[0483] Compound 146

Chemical Structure

[0484] 13 C NMR(101 MHz,DMSO-d6)δ174.17,144.01,138.40,135.34,134.37,132.57,131.68,131. 13,127.62,126.77,125.86,77.83,71.77,70.18,69.12,58.57,39.08,36.43.

[0485] HRMS (ESI-TOF): m / z theoretical value: C 18 H 22 N3O4[MI] + 344.1605, Actual value: 344.1609.

[0486] compound 147 [ka] (E) and (Z)-4-((2-(2-(2-methoxyethoxy)ethoxy)ethoxy)imino)-1,3-dimethyl-9-oxo-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.63(s,1H),9.56(s,1H),9.02(d,J=8.0 Hz,1H),8.34-8.09(m,3H),8.01-7.70(m,4H),4.78-4.58(m,4H),4.21-4.01(m,11H),3.90-3.80(m,4H),3.63- 3.42(m,10H),3.40-3.30(m,5H),3.16(d,J=12.0 Hz,5H).

[0487] 13C NMR(101 MHz,DMSO)δ175.23,174.18,144.73,144.01,138.39,137.03,135.84,135.36,13 4.81,133.19,132.56,131.67,131.13,131.03,130.53,129.74,128.12,127.62, 127.38, 126.61, 125.85, 125.38, 77.84, 76.78, 71.73, 70.42, 70.26, 70.22, 70.10, 70.05, 70.01, 69.12, 68.72, 58.54, 58.50, 41.50, 39.09, 36.70, 36.62, 36.42.

[0488] HRMS (ESI-TOF): m / z theoretical value: C 20 H 26 N3O5[MI] + 388.1867, Actual value: 388.1866.

[0489] compound 148 [ka] (E) and (Z)-4-((benzyloxy)imino)-1-butyl-3-methyl-9-oxo-2-(3,4,5-trimethoxyphenyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.01(d,J=8.1 Hz,1H),8.27(dd,J=7.8,1.6 Hz,1H),8.17-8.08(m,5H),7.93-7.89(m,1H),7.85-7.79(m,3H),7.72(t,J=7.4 Hz,3H),7.54-7.47(m,7H),7.45-7.30(m,9H),5.64(s,2H),5.54(s,2H),5.53(s,3H),4.10(d,J=3.4 Hz, 8H), 4.02 (s, 2H), 3.95 (s, 3H), 3.84 (s, 6H), 2.76 (s, 3H), 2.75 (s, 5H), 2.67 (s, 3H).

[0490] HRMS (ESI-TOF): m / z theoretical value: C20 H 26 N3O5[MI] + 540.2493, Actual value: 540.2495.

[0491] compound 149 [ka] (E) and (Z)-4-((benzyloxy)imino)-1,3-dimethyl-11-oxo-4,11-dihydro-1H-anthracene[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.67(s,1H),9.60(s,1H),9.54(s,1H),8.88(s,1H),8.82(s,1H),8.74(s,1H),8.31-8.13(m,4H),7.84 -7.68(m,4H),7.68-7.55(m,4H),7.51-7.38(m,6H),5.71(s,2H),5.61(s,2H),4.17(m,6H),4.02(s,3H),4.00(s,3H).

[0492] 13 C NMR(101 MHz,DMSO-d6)δ174.07,144.77,144.17,138.54,137.03,136.19,135.13,135.08,133.61,132.73,130.69,130.54,130.41,130.37,130 .17,130.10,129.85,129.75,129.40,129.26,129.23,129.17,129.13,129.04,128.92,128.47,126.26,125.23,122.71,79.71,78.95.

[0493] HRMS (ESI-TOF): m / z theoretical value: C 20 H 26 N3O5[MI] + 382.1550, Actual value: 382.1555.

[0494] compound 150 [ka] (E) and (Z)-4-((allyloxy)imino)-1,3-dimethyl-11-oxo-4,11-dihydro-1H-anthracene[2,3-d]imidazole-3-iodide 1 H NMR(400 MHz,DMSO-d6)δ9.67(s,2H),9.58(s,2H),8.98(s,2H),8.87(s,1H),8.75(s,1H),8.38-8.34(m,2H),8.23(dd,J=6.4,2.8 Hz,3H),7.87-7.79(m,5H),6.32-6.17(m,5H),5.18(dt,J=5.8,1.2 Hz,3H),5.07(d,J=6.0 Hz,2H),4.23-4.20(m,5H),4.20(s,3H),4.11(d,J=1.6 Hz,8H).

[0495] HRMS (ESI-TOF): m / z theoretical value: C 20 H 26 N3O5[MI] + 332.1334, Actual value: 332.1335.

[0496] Compound 151 [ka] (E) and (Z)-1,3-Dimethyl-4-(((4-nitrobenzyl)oxy)imino)-11-oxo-4,11-dihydro-1H-anthracene[2,3-d]imidazole-3-iodide 1 H NMR (400 MHz, DMSO-d6) δ9.74(s,1H),9.53(s,1H),8.94(s,1H),8.34-8.24(m,5H),7.86-7.79(m,3H),5.86(s,2H),4.18(s,3H),3.97(s,3H).

[0497] HRMS (ESI-TOF): m / z theoretical value: C 20 H 26 N3O5[MI] + 427.1401, Actual value: 427.1405.

[0498] The compounds obtained by the methods described in Examples 1 to 10 can be used to obtain the final imidazolium derivatives in Examples 11 to 13. In addition, other similar quinone oxime imidazolium derivatives and their synthetic intermediates can be easily prepared by the methods described in the above examples or preparation methods, or by some modified methods well known to those skilled in the art.

[0499] The effects of the compounds of the present invention were confirmed by the following tests.

[0500] Test Example 1: In vitro cancer cell proliferation inhibition test Test method: Pancreatic cancer cells CFPAC-1 were cultured in Dalbeco's modified Eagle medium supplemented with 10% FBS and 5% double antibody. CFPAC-1 cancer cells were seeded into a 96-well plate and incubated for 24 hours. The next day, various concentrations (100, 20, 10, 1, 0.1, 0.01, 0.001 μM) of test compounds and positive control drugs were added to each well, and a volume of fresh medium corresponding to the blank control was added. After 24 or 48 hours, cell proliferation was evaluated by the MTT formazan color reaction.

[0501] Test results: The compounds of the present invention effectively inhibit the proliferation of cancer cells, and their median lethal concentration IC 50 Values ​​are below 1 μM, with optimal compounds being able to achieve below 10 nM.

[0502] [Table 1]

[0503] In addition, the compounds (I), (II), (III) and (IV) of the present invention have good growth-inhibiting activity against other cancer cells, including non-small cell lung cancer cells (H460, H1299), liver cancer cells (HepG2), rectal cancer cells (HT29), leukemia cells (CCRF-CEM), prostate cancer cells (PC-3), ovarian cancer cells (SKOV-3), melanoma cells (A375), myeloma cells (RPMI-8226), esophageal cancer cells (TE-1), pancreatic cancer cells (CFPAC-1, PANC-1, SW1990, ASPC-1, BXPC-3), bladder cancer cells (5637), and gastric cancer cells (KATO-III). The results are shown below.

[0504] [Table 2]

[0505] Test Example 2: In vivo cancer cell proliferation inhibition test Test method: 3×10 7 CFPAC-1 pancreatic cancer cells were implanted subcutaneously in the armpits of Balb / c nude mice, and the tumor volume was 50–100 mm. 3 , 100~200mm 3 and 200mm 3 The administration started when the tumors grew to over 100 mm, and was given once every 3 days for a total of 7 times, with each administration at 7 mg / kg. The control group was injected with saline. Before each administration, the long and short diameters of the tumor were measured using calipers, and the mice were weighed until the day after the final administration. The tumor volume was calculated using the following formula:

[0506] Tumor volume (mm 3 )=1 / 2×[minor diameter (mm)] 2 × major axis (mm) Test results: In this test, the compounds (III) and (IV) of the present invention effectively inhibited the proliferation of cancer cells. For example, Examples 123, 124, 125 and 128 showed 100% proliferation inhibition activity at a dose of 7 mg / kg compared to the positive control group. Compounds 121, 132, 137, 138, 139, 140, 143, 144, 145, 146 and 147 showed inhibition rates of 80% or more and significant dose-dependency.

[0507] The compounds of the present invention also showed a good effect of inhibiting the proliferation of cancer cells in an animal model in which other cancer cells (non-small cell lung cancer A549) were transplanted.

[0508] Test Example 3: Toxicity test of compounds Test method: Compounds 121, 123, 124, 125, 128, 132, 137, 138, 139, 140, 143, 144, 145, 146, and 147 of the present invention were administered at a dose of 5 mg / kg via tail vein injection every day for 7 consecutive days, and the weight changes of BALB / c mice were monitored.

[0509] Test results: The mice did not show any obvious weight loss and were in good condition, whereas the mice administered gemcitabine in the positive control group showed obvious weight loss and were in poor condition.

[0510] Test Example 4: Antiviral activity Experimental method: 4.59mg of compound 125 was weighed into a 15ml centrifuge tube, 10ml of sterile water was added, and dissolved by vortexing until no obvious yellow particles were found. The solution was dispensed and stored at -20℃ with 200μl of each solution, 1mM concentration. 2.79mg of cidofovir (molecular weight 279) was weighed into a 15ml centrifuge tube, 10ml of sterile water was added, and dissolved. The solution was dispensed and stored at -20℃ with 200μl of each solution, 1mM concentration.

[0511] Plaque Experiments: 1. 293A cells were spread onto a 24-well plate at 150,000 cells per well and cultured at 37°C for 12 to 24 hours. When the cells had grown to 90%, they were used for the experiment.

[0512] 2.2% low melting point agarose gel was melted and then placed in a 56° C. water bath for preparation for use.

[0513] 3. Potency is 10 9 TCID 50 Adenovirus is 10 5The medium in the 24-well plate was discarded, 200 μl of the virus dilution was added to each well, and the plate was incubated in a 5% CO 2 incubator at 37° C. with shaking once every 30 minutes for a total of 1 hour.

[0514] 4. Test drug compound 125 and cidofovir are diluted 2-fold with 2×MEM (16μl compound 125 is added to 8ml 2×MEM, shaken to mix evenly, 4ml of the mixture is added to new 4ml 2×MEM and mixed evenly, and the five dilutions are 2μM, 1μM, 500nM, 250nM, 125nM by analogy, the highest concentration of compound 125 is 1μM; similarly, 400μl cidofovir is added to 7.6ml 2×MEM, shaken to mix evenly, 4ml of the mixture is added to new 4ml 2×MEM and mixed evenly, and the five dilutions are 50μM, 25μM, 12.5μM, 6.25μM, 3.125μM by analogy), and stored at 37℃ for use.

[0515] 5. Discard the virus solution, add an equal volume of agarose gel preheated to 56°C to 2xMEM, mix evenly, add 2 ml to each well, and incubate at room temperature for 30 minutes (gelation).

[0516] 6. The cells were incubated in a 37°C incubator, during which the viral replication status was observed under a fluorescence microscope.

[0517] Experimental results: In the cidofovir group, many blank plaques due to non-CPE were observed after 4 days, and non-CPE blank plaques also appeared in the low concentration group of compound 127 after 5 days. Compound 125 has an inhibitory effect on viral replication and has a significant dose-dependent inhibitory effect.

[0518] Compared with the prior art, the present invention has the following beneficial effects:

[0519] 1. The present invention systematically modifies the quinoimidazole skeleton to obtain a series of quinone oxime imidazole derivatives and quinone oxime imidazolium derivatives with novel structures.

[0520] 2. The present invention uses a new preparation method that is easier to synthesize, the raw materials are more readily available, the cost is low, and it is suitable for large-scale production.

[0521] The specific examples of the present invention have been described above. The present invention is not limited to the above specific embodiments, and those skilled in the art can make various changes or modifications without departing from the spirit and scope of the present invention.

Claims

1. A condensed quinone oxime imidazolium derivative having a structure represented by the following general formula (I) or (II): [Formula 1] (In the formula, Ring A is selected from an aromatic ring having no or more than one substituent, or a heteroaromatic ring having no or more than one substituent; R 1 , R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom, a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, or a heteroaryl group having no substituents or one or more substituents, In addition, A ring and R 1 , R 2 , R 3 and R 4 are selected from the groups in Group B; Group B includes: a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, a heteroaryl group having no substituents or one or more substituents, -OR a , -SR a , —O-lower alkylene-OR a , —O-lower alkylene-O-lower alkylene-OR a, —O-lower alkylene-O-lower alkylene-O-lower alkylene-OR a , —O-lower alkylene-NR a R b , —O-lower alkylene-O-lower alkylene-NR a R b , —O-lower alkylene-NR c -Lower alkylene-NR a R b , —O—CO—NR a R b , -SOR a , -SO 2 R a , -SO 2 N.R. a R b , -NR a -SO 2 R b , -NR a R b , -NR c -Lower alkylene-NR a R b , -N(-lower alkylene-NR a R b ) 2 , -NO 2 , -CN, -halogen, -CO 2 R a , -COO - , -CONR a R b , -CONR a -O-R b , -NR a -COR b , -NR a -CO-NR b R c , -OCOR a and -COR a and R a , R b and R care the same or different and each represents a hydrogen atom, a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, a heteroaryl group having no substituents or one or more substituents, a lower alkylene-(a 5- to 7-membered saturated heterocyclic group having no substituents or one or more substituents), a lower alkylene-(a cycloalkyl group having no substituents or one or more substituents), a lower alkylene-(an aryl group having no substituents or one or more substituents), or a lower alkylene-(a heteroaryl group having no substituents or one or more substituents), and the substituent refers to a lower alkyl group or a heteroalkyl group, X - is a counter anion including a halogen ion, a sulfonate ion, an acetate ion, a trifluoroacetate ion, a carbonate ion, a sulfate ion, etc., and when the anion on the substituent forms an inner salt with the imidazolium cation, X - does not exist.)

2. In the above structural formula, Ring A is a benzene ring, a naphthalene ring or NO 2 substituted benzene rings; R 1 is selected from -hydrogen atom, -lower alkyl group, -lower alkynyl group, -lower alkenyl group, -lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-O-aryl group, -lower chain alkyl-O-lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-O-lower chain alkyl-O-lower chain alkyl group-O-lower chain alkyl group, -aryl group, -5- to 7-membered saturated heterocycle, -heteroaryl group; R 2 is selected from lower chain alkyl groups, R 3is selected from -hydrogen atom, -lower chain alkyl group, -3 to 7 membered saturated cycloalkyl group, -heterocyclic group, -aryl group, -lower chain alkyl substituted aryl group, -halogen substituted aryl group, -heteroaryl group, -lower chain alkyl substituted heteroaryl group, -O-lower chain alkyl group, -S-lower chain alkyl group, -acyl group, -lower alkyl substituted acyl group; R 4 represents a hydrogen atom, a lower chain alkyl group, a lower chain alkenyl group, a lower alkynyl group, an aryl group, -CN, a 3- to 7-membered saturated cycloalkyl group, a halogen-substituted aryl group, a lower alkyl-substituted aryl group, a heteroaryl group, or CO 2 R a , -saturated heterocyclic group, -lower chain alkyl-OR a , -lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-S-lower chain alkyl group, -lower chain alkyl-O-lower chain alkyl-OR a is selected from R a The condensed quinone oxime imidazolium derivative according to claim 1, characterized in that: -is a lower chain alkyl group.

3. A condensed quinone oxime imidazole derivative having a structure represented by the following general formulas (III) and (IV) and its hydrochloride salt. [Case 2] (In the formula, Ring A is selected from an aromatic ring having no or more than one substituent, or a heteroaromatic ring having no or more than one substituent; R 1 , R 3 and R 4are the same or different and each represents a hydrogen atom, a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, or a heteroaryl group having no substituents or one or more substituents, In addition, A ring and R 1 , R 2 , R 3 and R 4 may be selected from the groups in Group B; Group B includes: a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, a heteroaryl group having no substituents or one or more substituents, -OR a , -SR a , —O-lower alkylene-OR a , —O-lower alkylene-O-lower alkylene-OR a , —O-lower alkylene-O-lower alkylene-O-lower alkylene-OR a , —O-lower alkylene-NR a R b , —O-lower alkylene-O-lower alkylene-NR a R b , —O-lower alkylene-NR c -Lower alkylene-NR a R b , —O—CO—NR a R b , -SOR a , -SO 2 R a, -SO 2 N.R. a R b , -NR a -SO 2 R b , -NR a R b , -NR c -Lower alkylene-NR a R b , -N(-lower alkylene-NR a R b ) 2 , -NO 2 , -CN, -halogen, -CO 2 R a , -COO - , -CONR a R b , -CONR a -O-R b , -NR a -COR b , -NR a -CO-NR b R c , -OCOR a and -COR a and R a , R b and R c are the same or different and each represents a hydrogen atom, a lower chain alkyl group having no substituents or one or more substituents, a lower chain alkenyl group having no substituents or one or more substituents, a lower alkynyl group having no substituents or one or more substituents, a saturated heterocyclic group having no substituents or one or more substituents, a cycloalkyl group having no substituents or one or more substituents, a cycloalkenyl group having no substituents or one or more substituents, an aryl group having no substituents or one or more substituents, or a heteroaryl group having no substituents or one or more substituents, where the substituent refers to a lower alkyl group or a heteroalkyl group.

4. In the above structural formula, The A ring is a -benzene ring, a -naphthalene ring or NO 2 substituted benzene rings; R 1is selected from -hydrogen atom, -lower alkyl group, -lower alkynyl group, -lower alkenyl group, -lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-O-aryl group, -lower chain alkyl-O-lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-O-lower chain alkyl-O-lower chain alkyl group-O-lower chain alkyl group, -aryl group, -5- to 7-membered saturated heterocycle, -heteroaryl group; R 3 is selected from -hydrogen atom, -lower chain alkyl group, -3 to 7 membered saturated cycloalkyl group, -heterocyclic group, -aryl group, -lower chain alkyl substituted aryl group, -halogen substituted aryl group, -heteroaryl group, -lower chain alkyl substituted heteroaryl group, -O-lower chain alkyl group, -S-lower chain alkyl group, -acyl group, -lower alkyl substituted acyl group; R 4 represents a hydrogen atom, a lower chain alkyl group, a lower chain alkenyl group, a lower alkynyl group, an aryl group, -CN, a 3- to 7-membered saturated cycloalkyl group, a halogen-substituted aryl group, a lower alkyl-substituted aryl group, a heteroaryl group, or CO 2 R a , -saturated heterocyclic group, -lower chain alkyl-OR a , -lower chain alkyl-O-lower chain alkyl group, -lower chain alkyl-S-lower chain alkyl group, -lower chain alkyl-O-lower chain alkyl-OR a is selected from R a The condensed quinone oxime imidazole derivative and its hydrochloride salt according to claim 3, wherein is a lower chain alkyl group.

5. A pharmaceutical composition comprising one or more quinone oxime imidazolium derivatives according to claim 1 or 2 and a pharma- ceutically acceptable carrier.

6. A pharmaceutical composition comprising one or more of the condensed quinone oxime imidazole derivatives or hydrochlorides thereof according to claim 3 or 4, and a pharma- ceutically acceptable carrier.

7. 7. Use of the pharmaceutical composition according to claim 5 or 6 in the manufacture of an anti-cancer, anti-bacterial or anti-viral medicament.

8. A method for producing the condensed quinone oxime imidazolium derivative according to claim 1 or 2 and the condensed quinone oxime imidazole derivative according to claim 3 or 4, comprising the steps of: A protic solvent is used as a solvent to obtain a substituted quinone imidazole derivative [C3] (V) to R 1 O.N.H. 2 Under the catalysis of HCl and a weak base, or the corresponding R 1 O.N.H. 2 and a weak base hydrochloride to form an oxime-imidazole derivative. [C4] (III) and [C5] A step A for obtaining (IV); The quinone oxime imidazole derivative (III) or (IV) is reacted with the corresponding halide reagent R in an organic solvent. 2 and step B of reacting X with X in an N-alkylation reaction to obtain a quinone oxime imidazolium derivative (I) or (II).

9. In step A, the quinone imidazole derivative [C6] (V) and R 1 O.N.H. 2 The method according to claim 8, characterized in that the molar ratio of HCl to weak base is 1:1.2-5:0.001-0.01, the protic solvent is selected from methanol, ethanol, isopropanol, the weak base is selected from pyridine, triethylamine, potassium carbonate, the reaction temperature is 90-125°C, and the reaction time is 12-48 hours.

10. In step B, the quinone oxime imidazole derivative (III) or (IV) is reacted with a halide reagent R 2The method according to claim 8, wherein the molar ratio of X to X is 1:1 to 1:100, the solvent is selected from acetonitrile, ethyl acetate, and tetrahydrofuran, the reaction temperature is 50 to 120° C., and the reaction time is 8 to 48 hours.

Citation Information

Patent Citations

  • 1, 4-naphthoquinone / anthraquinone imidazole derivatives and preparation and application thereof

    CN108530365A

  • Methyl naphthoquinone imidazole derivative and preparation method and application thereof

    CN108794403A

  • Antiretroviral agent

    JP1988310830A

  • Novel fluoronaphthacenediones, their glycosilated derivative and their preparation

    JP1991209343A

  • Imidazobenzoquinones and prophylactic / therapeutic agents for hypertension / congestive heart failure containing them as active ingredients

    JP1994507620A